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Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation in
the Development of Spectinamides, a Novel Class of Anti-Tuberculosis Agents
Abstract
New chemotherapeutic agents are urgently needed to control the spread of multidrug-resistant (MDR)
and extensively drug-resistant (XDR) forms of tuberculosis, which still remains an important public health
challenge globally. Recently, spectinamides have emerged as a novel class of anti-tuberculosis agents
that overcomethe native drug efflux. Spectinamides bind to the 30S bacterial ribosomal subunit which
interferes with ribosomal translocation, and ultimately results in inhibition of protein synthesis. They have
potent in vitro activity against drug resistant Mycobacterium tuberculosis (Mtb), and also demonstrated
sustained efficacy in (Mtb)-infected mouse models. Pharmacokinetic (PK)/ pharmacodynamic (PD)
analyses play a critical role in identifying the optimum dosing regimen for new treatments. In this
dissertation, I hypothesized that the application of translational PK/PD modeling and simulation
techniques would facilitate rational dosage regimen design for spectinamides.
To characterize the dose-exposure-response of Lee 1810, a dose-fractionation study was performed in
BALB/c mice infected with a low dose aerosol of (Mtb). Dosing with different dosing regimens was
continued for 4 weeks with two blood samples obtained from each mice in the last week, followed by a
washout period after which the mice were sacrificed and the lungs removed for measurement of colony
forming units (CFU). Drug concentrations in plasma were analyzed with a validated LC-MS/MS method
followed by a population PK analysis which also included as anchor point the data of a PK study in
healthy mice with intensive sampling. A model for natural bacterial growth in Mtb infection in untreated
mice was built from data on the natural history of Mtb infection in mice obtained from previously
performed studies and from the literature. Based on the individual post hoc estimates from the
population PK modeling, a sequential PK/PD analysis was performed by linking the PK model with the
bacterial growth model via an exposure-dependent bacterial kill function that included a sigmoid Emax
model for describing the overall rate of change in lung CFU with different dosing regimens. A twocompartment model with first-order absorption was used to describe the pharmacokinetics of Lee 1810.
The average absorption rate constant (Ka), clearance (CL/F), volume of the central compartment (Vc/F),
intercompartmental clearance (Q/F), and volume of the peripheral compartment (Vp/F) was estimated to
be 2.31 h-1,1.17 L/h/kg, 0.435 L/kg, 0.0191 L/h/kg, and 0.161 L/kg, respectively. The inter-individual
variability in CL/F was estimated as 19.9 %. The pharmacokinetics of Lee 1810 was found to be different
between healthy and infected mice with the later having 56.5% lower CL/F, 69% lower Vc/F and 69.6%
lower Q/F. The two-subpopulation model could successfully describe the natural bacterial growth. The
replication rate constant (Krep) of Mtb was calculated as 0.0327 h-1 which is consistent with values
reported in the literature. The death rate constant induced by the immune system (Kir) was 0.00303 h-1,
cell countof fast growing population at the initiation of the infection (N1,0) was 1.93 Log CFU and
maximum number of bacteria (Nmax) was 6.44 Log CFU. The inter-individual variability in Krep and Nmax
was estimated as 70.8 % and 54.7%, respectively. The bacterial kill induced by the drug was described
using a sigmoid Emax model. The drug effect parameters (EC50), maximum kill rate (Emax) and Hill
coefficient (y), were estimated as 239 μg/mL, 11.9 h-1 and 2.40 respectively. A Hill coefficient
substantially greater than 1 is a typical characteristic of concentration-dependent killing. The
concentration dependent killing characteristic of Lee 1810 supports its intermittent dosing.
Poor permeability of spectinamides across the gut limits its oral use. Additionally, since the lungs are the
main site of infection in pulmonary TB, the efficacy of lead spectinamide Lee 1599 was evaluated after
intratracheal (IT) administration in a mouse model of Mtb infection. A dose of 200 mg/kg TIW (3 days a

week) for 28 days resulted in excellent efficacy with 2.2 Log CFU reduction in the lungs. Based on these
observations, a comparative biodistribution study of Lee 1599 was performed after IT and SC
administration in mice. Plasma and tissue samples were collected at pre-specified time points. The drug
was extracted from plasma and homogenized tissues after protein precipitation and analyzed with an LCMS/MS assay. The rate and extent of absorption was almost two times higher with IT as compared to SC
administration. As expected, the highest exposure of Lee 1599 after IT administration was attained in the
lungs, which was 2.5 times higher than in plasma. This is highly desirable as lungs are the main site of
infection in pulmonary tuberculosis. Overall, this study supports the pulmonary route as a potential
pathway for the treatment of tuberculosis with Lee 1599.
Physiologically-based pharmacokinetic (PBPK) modeling and simulation is a powerful methodology used
in support of dose selection for first-in-human studies. The objective was to develop a PBPK model for
describing pharmacokinetics of Lee 1599 in rats and mice, and to extrapolate this PK behavior to
humans. 10 mg/kg of Lee 1599 was administered intravenously to rats and 200 mg/kg subcutaneously to
mice. The PBPK model was developed based on the observed rat plasma concentrations,
physicochemical properties of Lee 1599, and in vitro data from its metabolism, protein binding and
permeability. The concentration-time profile of Lee 1599 in rats was well described by the optimized PBPK
model. The model was prospectively qualified by PBPK scaling from rats to mice and comparing
predicted murine concentration-time profiles to observed plasma concentrations. This model was also
successful in predicting murine PK with observed PK parameters within two-folds of predicted values.
The model predicted, weight normalized human clearance of 0.25 L/h/kg was as expected less than the
values in rats (0.666 L/h/kg) and mice (1.25 L/h/kg). The PBPK model predicted, a dose of 7.5 mg/kg and
27.5 mg/kg administered once daily via intravenous administration will be required to attain similar
exposure as observed in mice after subcutaneous administration of 50 mg/kg and 200 mg/kg
respectively. This model suggests that an efficacious systemic exposure can be achieved with daily
doses feasible in humans, and may be useful during drug development for understanding the dose
requirements for future human studies.
In conclusion, translational PK/PD approaches have been successfully used for the further development
and characterization of spectinamides leads Lee 1599 and Lee 1810. The results from the above studies
will be helpful in identifying and optimizing the dosing regimens which can strike a balance between
bacterial reduction, adverse effects, and emergence of resistance.
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ABSTRACT
New chemotherapeutic agents are urgently needed to control the spread of
multidrug-resistant (MDR) and extensively drug-resistant (XDR) forms of tuberculosis,
which still remains an important public health challenge globally. Recently,
spectinamides have emerged as a novel class of anti-tuberculosis agents that overcome
the native drug efflux. Spectinamides bind to the 30S bacterial ribosomal subunit which
interferes with ribosomal translocation, and ultimately results in inhibition of protein
synthesis. They have potent LQYLWUR activity against drug resistant 0\FREDFWHULXP
WXEHUFXORVLV (0WE), and also demonstrated sustained efficacy in 0WE-infected mouse
models. Pharmacokinetic (PK)/ pharmacodynamic (PD) analyses play a critical role in
identifying the optimum dosing regimen for new treatments. In this dissertation, I
hypothesized that the application of translational PK/PD modeling and simulation
techniques would facilitate rational dosage regimen design for spectinamides.
To characterize the dose-exposure-response of Lee 1810, a dose-fractionation
study was performed in BALB/c mice infected with a low dose aerosol of 0WE. Dosing
with different dosing regimens was continued for 4 weeks with two blood samples
obtained from each mice in the last week, followed by a washout period after which the
mice were sacrificed and the lungs removed for measurement of colony forming units
(CFU). Drug concentrations in plasma were analyzed with a validated LC-MS/MS
method followed by a population PK analysis which also included as anchor point the
data of a PK study in healthy mice with intensive sampling. A model for natural bacterial
growth in 0WE infection in untreated mice was built from data on the natural history of
0WE infection in mice obtained from previously performed studies and from the literature.
Based on the individual SRVWKRF estimates from the population PK modeling, a
sequential PK/PD analysis was performed by linking the PK model with the bacterial
growth model via an exposure-dependent bacterial kill function that included a sigmoid
Emax model for describing the overall rate of change in lung CFU with different dosing
regimens. A two-compartment model with first-order absorption was used to describe the
pharmacokinetics of Lee 1810. The average absorption rate constant (Ka ), clearance
(CL/F), volume of the central compartment (Vc /F), intercompartmental clearance (Q/F),
and volume of the peripheral compartment (Vp /F) was estimated to be 2.31 h-1,1.17
L/h/kg, 0.435 L/kg, 0.0191 L/h/kg, and 0.161 L/kg, respectively. The inter-individual
variability in CL/F was estimated as 19.9 %. The pharmacokinetics of Lee 1810 was
found to be different between healthy and infected mice with the later having 56.5%
lower CL/F, 69% lower Vc /F and 69.6% lower Q/F. The two-subpopulation model could
successfully describe the natural bacterial growth. The replication rate constant (Krep ) of
0WE was calculated as 0.0327 h-1 which is consistent with values reported in the literature.
The death rate constant induced by the immune system (Kir ) was 0.00303 h-1, cell count
of fast growing population at the initiation of the infection (N1,0 ) was 1.93 Log CFU and
maximum number of bacteria (Nmax ) was 6.44 Log CFU. The inter-individual variability
in Krep and Nmax was estimated as 70.8 % and 54.7%, respectively. The bacterial kill
induced by the drug was described using a sigmoid Emax model. The drug effect
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parameters (EC50 ), maximum kill rate (Emax ) and Hill coefficient (Ȗ), were estimated as
239 μg/mL, 11.9 h-1 and 2.40 respectively. A Hill coefficient substantially greater than 1
is a typical characteristic of concentration-dependent killing. The concentrationdependent killing characteristic of Lee 1810 supports its intermittent dosing.
Poor permeability of spectinamides across the gut limits its oral use. Additionally,
since the lungs are the main site of infection in pulmonary TB, the efficacy of lead
spectinamide Lee 1599 was evaluated after intratracheal (IT) administration in a mouse
model of 0WE infection. A dose of 200 mg/kg TIW (3 days a week) for 28 days resulted
in excellent efficacy with 2.2 Log CFU reduction in the lungs. Based on these
observations, a comparative biodistribution study of Lee 1599 was performed after IT
and SC administration in mice. Plasma and tissue samples were collected at pre-specified
time points. The drug was extracted from plasma and homogenized tissues after protein
precipitation and analyzed with an LC-MS/MS assay. The rate and extent of absorption
was almost two times higher with IT as compared to SC administration. As expected, the
highest exposure of Lee 1599 after IT administration was attained in the lungs, which
was 2.5 times higher than in plasma. This is highly desirable as lungs are the main site of
infection in pulmonary tuberculosis. Overall, this study supports the pulmonary route as a
potential pathway for the treatment of tuberculosis with Lee 1599.
Physiologically-based pharmacokinetic (PBPK) modeling and simulation is a
powerful methodology used in support of dose selection for first-in-human studies. The
objective was to develop a PBPK model for describing pharmacokinetics of Lee 1599 in
rats and mice, and to extrapolate this PK behavior to humans. 10 mg/kg of Lee 1599 was
administered intravenously to rats and 200 mg/kg subcutaneously to mice. The PBPK
model was developed based on the observed rat plasma concentrations, physicochemical
properties of Lee 1599, and LQYLWUR data from its metabolism, protein binding and
permeability. The concentration-time profile of Lee 1599 in rats was well described by
the optimized PBPK model. The model was prospectively qualified by PBPK scaling
from rats to mice and comparing predicted murine concentration-time profiles to
observed plasma concentrations. This model was also successful in predicting murine PK
with observed PK parameters within two-folds of predicted values. The model predicted,
weight normalized human clearance of 0.25 L/h/kg was as expected less than the values
in rats (0.666 L/h/kg) and mice (1.25 L/h/kg). The PBPK model predicted, a dose of 7.5
mg/kg and 27.5 mg/kg administered once daily via intravenous administration will be
required to attain similar exposure as observed in mice after subcutaneous administration
of 50 mg/kg and 200 mg/kg respectively. This model suggests that an efficacious
systemic exposure can be achieved with daily doses feasible in humans, and may be
useful during drug development for understanding the dose requirements for future
human studies.
In conclusion, translational PK/PD approaches have been successfully used for
the further development and characterization of spectinamides leads Lee 1599 and Lee
1810. The results from the above studies will be helpful in identifying and optimizing the
dosing regimens which can strike a balance between bacterial reduction, adverse effects,
and emergence of resistance.
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CHAPTER 1. TRANSLATIONAL PK/PD OF ANTI-INFECTIVE
THERAPEUTICS*
Introduction
The treatment options available to combat infectious diseases are becoming
increasingly limited due to a rising incidence of resistance among bacteria against the
currently used antibiotics. Additionally, the discovery and development of new
antibiotics has slowed down because of limited incentives for the pharmaceutical industry
in this therapeutic area and a high benefit-risk ratio of existing antibiotics [1]. This
necessitates prudent use of the currently clinically available as well as newly developed
antibiotics. One of the key requirements for preserving clinical efficacy of antibiotics and
avoiding tolerance development is to identify the optimum dosing schedule for maximum
bacterial kill and minimal emergence of resistance [2]. Although standard
pharmacokinetic (PK)/ pharmacodynamic (PD) indices have been used for this purpose
with some clinical success, this approach is associated with several drawbacks. One of
them is the high dependence upon the minimum inhibitory concentration (MIC), which is
limited to a single efficacy endpoint that does not take into account the entire time course
of effect and may vary between treated individuals and bacterial strains [3].
Translational PK/PD modeling and simulation has emerged as an alternative
strategy to characterize the relationship between dose, exposure and response for
identifying the most suitable dosing regimen. For example, infections with
0\FREDFWHULXPWXEHUFXORVLV are usually characterized by the presence of both
multiplying and non-multiplying bacteria, and most antibiotics are usually more effective
in killing multiplying rather than non-multiplying microorganisms. Mechanistic PK/PD
models have successfully been applied to delineate the independent drug effects
associated with killing of the multiplying and the non-multiplying bacterial populations
[4]. In another example, different dosing regimens with similar exposure to colistin
resulted in greater emergence of resistance with longer dosing intervals. Based on this
observation, PK/PD models have subsequently been used for simulating untested dosing
scenarios and developing an optimum dosing regimen for colistin [5].
It is the purpose of this review to provide an overview on the mechanism-based
PK/PD models applied in translational PK/PD modeling for antibiotics.
PK/PD Indices
For decades, the PK/PD relationships of antibiotics have been categorized with
three different PK/PD indices, which rely on a summary measurement of LQYLYR drug
*This chapter adapted with permission. Rathi, C., R.E. Lee, and B. Meibohm,
7UDQVODWLRQDO3.3'RIDQWLLQIHFWLYHWKHUDSHXWLFV Drug Discov Today Technol, 2016.
21-22: p. 41-49[6].
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exposure relative to the MIC, determined LQYLWUR using serial dilution steps [7].
Usually, only free rather than total drug concentrations are considered as only free drug
which is not bound to plasma proteins exerts the pharmacological activity. Standardized
notations for these PK/PD indices are AUC/MIC, Cmax/MIC and T>MIC. AUC/MIC is
the ratio of area under the free plasma concentration-time curve relative to MIC,
Cmax/MIC is the ratio of free peak plasma concentration relative to MIC, and T>MIC is
the cumulative percentage of a time period that the free concentration is above MIC.
Antibiotics that are classified as having their efficacy driven by T>MIC show timedependent killing which suggests that the antibacterial effect is at its maximum with
concentrations just above the MIC and no further improvement in killing is obtained by
further increasing the concentrations. Cmax/MIC best describes antibiotics which follow
concentration-dependent killing and require maximum peak antibiotic concentration for
maximum efficacy, whereas AUC/MIC is representative of the antibiotics which elicit
both time- and concentration-dependent killing [3]. Although the MIC based approach
has been widely used by clinicians for designing dosing regimens and can be useful to
predict the effect of dose fractionation on antibacterial activity, this approach is
associated with several limitations.
PK/PD indices rely heavily on MIC. Measurement of MIC is associated with
substantial uncertainty and variability because of the two-fold dilution technique used for
its assessment and the interpretation as implied binary response, which considers efficacy
only above MIC and no killing below MIC. Furthermore, MIC varies across patient
populations and bacterial strains, and may change with time in the same patient [8]. Thus,
MIC-based approaches ignore the dynamics of bacterial killing with time. It is typically
assumed that a PK/PD index determined in a preclinical species or population can be
extrapolated to another patient population. However, PK/PD indices have been found to
vary among different patient populations, species, and disease conditions, and one of the
reasons is associated with differences in the pharmacokinetics of the antibiotic in these
groups [9, 10])RUH[DPSOHLQFDVHRIȕ-lactam antibiotics, the PK/PD index has been
observed to change from T>MIC to AUC/MIC as the half-life increases in renally
impaired patients. Similarly, decreases in half-life will shift the PK/PD index from
AUC/MIC to T>MIC [11]. Thus, the value for PK/PD indices as guiding tool for dosage
regimen design seems questionable.
One approach to overcome these drawbacks is the use of mechanism-based
PK/PD modeling. Rather than relying on point estimates that integrate PK and PD factors
of the host, the drug and the microorganism into one index, a mechanism-based PK/PD
model has sufficient granularity to allow adjustment to changes in one of several of the
PK and PD parameters as needed by changing clinical situations. In addition, PK/PD
models reflect the gradual killing effect on bacteria with changing drug exposure rather
than dichotomous all-or-nothing effects as implied by MIC values. Finally, PK/PD
models consider the time-courses of bacterial growth and killing in relation to time
courses of drug concentrations rather than time-integrated measures as used for the
indices. Overall, these advantages allow for a more flexible, realistic and dynamic
interplay of drug, host and microorganism-related factors that are ultimately predictive of
bacterial killing and therapeutic efficacy.
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Mechanism Based PK/PD Modeling
Mechanism based PK/PD models take into consideration the time course of
bacterial count based on LQYLWUR, LQYLYR and clinical information. These models are
composed of three basic components: (i) a component that describes the bacterial growth
kinetics, (ii) a component that describes the pharmacokinetics of the drug, and (iii) a
component that integrates the effect of the drug concentration on bacterial turnover.
Bacterial growth kinetics
The simplest model component used for describing the bacterial growth kinetics
consists of a single bacterial compartment with a first-order rate constant for bacterial
Krep replication (Krep) and a first order rate constant for death of the bacteria (Krep).
Equation 1-1 and Figure 1-1A describe the mono-exponential increase in microbial
number seen in the absence of drug treatment [12], where N is the number of bacteria.
ௗே
ௗ௧

Eq. 1-1

= ܭ × ܰ െ ܭௗ௧ × ܰ

Quite often only the net process between bacterial growth and kill is quantified, with a
first-order rate constant Kgrowth = Krep - Kdt , also called Knet , since it is difficult to
separately estimate both the replication and death rate constants with limited data [13].
The underlying assumption of this model is that the microbial population is homogenous
having the same turnover rate constants, which is an oversimplification of the real
scenario as microbial populations are usually known to be heterogeneous with multiple
subpopulations with distinct metabolic states and drug resistance profiles [8].
In the absence of antibiotics, the bacterial number N eventually approaches a
maximum Nmax when limitation in nutrients and bacterial density limit further growth. In
this steady-state condition there is no net change in the microbial population. There are
three ways to describe these capacity limited growth curves:
Using a logistic growth function [14, 15]:
ௗே
ௗ௧

= ܭ௪௧ × ቀ1 െ

ே
ேೌೣ

Eq. 1- 2

ቁ×ܰ

Using a saturable, non-linear function [16]:
ௗே
ௗ௧

=ቀ

ீೌೣ
ேఱబ ାே

Eq. 1- 3

ቁ×ܰ

where VGmax is the bacterial maximum growth in bacterial count per time, and N50 is N
at which the bacterial growth is half-maximal.
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Figure 1-1. Models for bacterial growth kinetics
A) One cell population model, B) Two cell population model with different cell growth
status.
Abbreviations: N, Number of bacteria; Krep , first-order replication rate constant; Kdt ,
first-order death rate constant; S, Number of bacteria in growing state; R, Number of
bacteria in resting state.
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Using a model where transformation from the growing (S) to the resting stage (R)
occurs when the total microbial count approaches the stationary phase [17] (Figure
1-1B).
ௗௌ
ௗ௧
ௗோ
ௗ௧

= = ܭ × ܵ െ ܭௗ௧ × ܵ െ (ܭ െ ܭௗ௧ ) × ቀ

ௌାோ

ேೌೣ

= (ܭ െ ܭௗ௧ ) × ቀ

ௌାோ

ேೌೣ

ቁ × ܵ + ܭ௦ × ܴ

ቁ × ܵ െ ܭ௦ × ܴ െ ܭௗ௧ × ܴ

Eq. 1- 4
Eq. 1- 5

where S and R are the number of growing and resting bacteria, respectively. A high total
bacterial load is assumed to potentiate the transformation from S to R. The transfer back
to the growing stage (Krs ) is usually assumed to be negligible during LQYLWUR time-kill
experiments and therefore in those cases fixed to 0.
In some instances, additional delay functions have been introduced to characterize
the growth delay observed during the first hours after the initiation of growth experiments
when the microbes have not yet reached the logarithmic growth phase. For example,
inverse mono-exponential functions with asymptotic increase such as 1-e-į×t have been
used as multiplier for Krep or Kgrowth , where į is a first-order rate constant characterizing
the dissipation of the delay [18, 19].
Pharmacokinetics
The pharmacokinetic model component is used for characterizing the
concentration profile of a drug over a time period. Traditional compartmental modeling
approaches are generally used to describe the pharmacokinetics with one- or multicompartment systems. For example, in an LQYLWUR chemostat-based PK/PD model system
[19], the drug concentration can be described with a one-compartment model with monoexponential decrease with time according to
ௗ
ௗ௧

Eq. 1-6

= െ ܭ ×ܥ

where C is the concentration of the drug and Ke is the first-order elimination rate constant
of the drug.
The pharmacokinetic profile of a new drug is usually established in healthy
subjects during the initial clinical phase of drug development. The pharmacokinetics may
however be altered under pathophysiologic conditions in a diseased population. For
example, drugs which are primarily renally cleared may reach higher systemic exposure
in patients with renal impairment compared to healthy individuals. In these cases,
creatinine clearance is typically found to be a significant covariate and can be used to
guide patient customized dosing [20]. Disease conditions can also cause changes in the
body fluids and protein binding which may ultimately affect tissue distribution and the
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free fraction of the drug [21], and may thus need to be considered in the pharmacokinetic
model component of mechanism based PK/PD models.
Many microbial infections are localized in extravascular tissues rather than blood
or plasma [22]. The concentration at the site of infection may in these cases be different
from plasma concentrations due to drug distribution processes and may thereby
complicate the accurate assessment of optimal dosing regimens [23]. For example,
concentration-time profiles of antibiotics in epithelial lining fluid in the lungs was found
to be different from plasma with concentration ratios ranging from <0.1 to 3 [24]. In
addition to efficacy, organ or tissue concentrations may also be of interest with regard to
toxicity [25]. Techniques like microdialysis have been used for measurement of drug
concentrations in tissue/organs [26]. Tissue distribution of antibiotics may be predicted
using physiologically-based pharmacokinetic (PBPK) modeling [27, 28]. Recently, a
PBPK model incorporating a multi-compartment permeability-limited lung model was
used to simulate the pharmacokinetics of anti-tuberculosis agents in plasma, lungs and its
sub-compartments where the mycobacteria reside in the host [29]. This model also
provides a framework for predicting the lung concentrations of novel anti-tuberculosis
agents.
Pharmacodynamics
The drug effect E can be modeled to either inhibit bacterial replication or
potentiate bacterial killing. The relationship between drug concentration and its
antimicrobial effect is usually described using an ordinary (Ȗ ) or a sigmoidal (Ȗz1)
inhibitory Emax model. The general expression for the bacterial growth kinetics is then
modified to Equation 1-7:
ௗே
ௗ௧

Eq. 1-7

= ܧ × ܭ × ܰ െ ܧௗ௧ × ܭௗ௧ × ܰ

Drug effect decreasing the replication rate can then be modeled as
ܧ = 1 െ

ூೌೣ × ംభ

Eq. 1-8

ംభ

ூఱబ ା ംభ

Drug effect increasing the death rate can be modeled as
ܧௗ௧ = 1 +

ாೌೣ × ംమ

Eq. 1-9

ംమ

ாఱబ ା ംమ

Here Emax and Imax represent the maximum increase or decrease in effect, EC50 and IC50
represent the concentrations of drug that produce half of Emax and Imax , and Ȗ1 and Ȗ2 are
the sigmoidicity coefficients. In Equation 1-8 and Equation 1-9, the effect corresponds
to a unitless fractional change in the rate constant with Emax and Imax representing the
maximum achievable fractional change.
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Alternatively to these proportional effect models, the increase in the death rate
can also be modeled as an additive effect (Figure 1-2A):
ௗே
ௗ௧

= ܭ × ܰ െ ܭௗ௧ × ܰ െ

ூೌೣ × ം
ം

ூఱబ ା ം

Eq. 1-10

×ܰ

In Equation 1-10, the effect corresponds to an additional kill-rate constant contributed by
the drug with Imax , representing the maximum achievable drug-imposed kill-rate constant
having the unit 1/time.
Combination Therapy
Combination therapy of antibiotics has been found to be useful as it may improve
efficacy, increase patient compliance by optimizing dosing schedules, reduce toxicity,
and suppress the emergence of resistance [30]. There is high potential for
pharmacodynamic drug-drug interactions when antibiotics of a combination therapy act
on the same or different molecular targets (serial or parallel) in the same pathogen,
resulting in additive, synergistic or antagonistic interaction [31]. The concentration-effect
relationship for two-drug combinations results in a three-dimensional response surface
which is usually characterized quantitatively using the response surface analysis as
described by Equation 1-11 [32, 33]:
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Eq. 1-11

where C1 and C2 are the concentrations of drug 1 and drug 2 in the combination therapy;
IC50,1 is the concentration for which the effect is half maximal for drug 1 when present
alone; IC50,2 is the concentration for which the effect is half maximal for drug 2 when
present alone; Ȗ1 and Ȗ2 are the sigmoidicity coefficients for drug 1 and drug 2,
respectively; Imax is the maximum bacterial killing rate constant; Ȧ is the interaction
parameter; and I is the combined effect of both the drugs. The summation of the first and
second term on the right side of the equation defines the additive effect whereas the third
term is the drug interaction term. The combination effect is additive when Ȧ = 0, is
synergistic when Ȧ >> 0, and is antagonistic when Ȧ << 0.
The kinetics of bacterial killing for the combination therapy can then be described
using Equation 1-12 with modification of the drug effect term by taking a similar
approach as described above for the response surface analysis [34].
ം

ௗே
ௗ௧



 ×
ூೌೣ × ൬ భ ା  మ ା ఠ× భ ×మ
൰
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= ܭ × ܰ െ ܭௗ௧ × ܰ െ ቌ

ଵା൬

ം
భ
మ
భ ×మ
ା
ା
ఠ×
൰
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ቍ × ܰ Eq. 1-12

Figure 1-2. PK/PD models consisting of pharmacokinetic component, bacterial growth model, and pharmacodynamic link
A) One bacterial population with additive effect on death rate. B) Subpopulation approach for antibiotic resistance with two or more
bacterial populations each having different drug sensitivity. C) Adaptation approach for drug resistance with adaptation factor
modulating drug sensitivity.
Abbreviations: C, drug concentration; N/N1 /N2 /Nx , number of bacteria in different bacterial populations; Ke , first order drug
elimination rate constant; Krep , first-order replication rate constant; Kdt , first-order death rate constant; Imax , maximum achievable
effect (subscripts indicate different values for different bacterial populations); IC50 , drug concentration producing 50% of Imax
(subscripts indicate different values for different bacterial populations); Ȗ, is the sigmoidicity factor; Į , adaptation factor.
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when Ȧ is the interaction parameter; and Ȗ is the sigmoidicity coefficient for the
combination therapy, under the assumption that in the response surface analysis, Ȗ1 = Ȗ2 .
Antibiotic Resistance
Antibiotic resistance can be mathematically explained either by an increase in
IC50 or decrease in Imax . Prior knowledge about the mechanism of resistance can be used
as a rationale for choosing the appropriate model. When reduced drug sensitivity can
completely be overcome with a higher dose, an increase in IC50 is suggested as the
probable mechanism for resistance. If even high doses are unable to achieve the
maximum effect, however, then a decrease in Imax might be the more appropriate
mechanism [13].
A variety of PK/PD models have been proposed for describing antibiotic
resistance. These models can be broadly categorized into subpopulation approaches and
adaptation approaches.
Subpopulation approaches
The more commonly used subpopulation approaches assume that the total
bacterial population is composed of several discrete subpopulations with different drug
susceptibility as shown in Figure 1-2B. These subpopulations are considered to be
present even in the initial inoculum. Subsequent treatment with antibiotic leads to
predominant killing of susceptible subpopulations along with selective replication of the
less susceptible subpopulations resulting overall in regrowth. More than one differential
equation is used simultaneously with each equation representing one bacterial
subpopulation (often with different drug susceptibilities) [35]. A variation of the
subpopulation model is one in which new drug resistant mutants are formed from the
growing subpopulation with a first-order mutation rate during the experiment resulting in
regrowth [36].
A modification of the sub-population approach could potentially be used to
facilitate development of new generation anti-infectives which do not necessarily kill the
bacteria. For example, Bezlotoxumab, a fully human monoclonal antibody, was found to
decrease the rate of recurrence of &ORVWULGLXPGLIILFLOH infection in patients treated with
standard-of-care antibiotics [37]. Bezlotoxumab acts by neutralizing the exotoxin B
thereby averting its interaction with colonic cells and the associated inflammation. One of
the possible approaches to characterize the PK/PD in this scenario could be a modified
subpopulation model where the Bezlotoxumab induced toxin neutralization is modeled in
parallel with the killing effect imposed by the standard-of-care treatment on the
susceptible &ORVWULGLXPGLIILFLOH population.
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Adaptation approaches
An alternative to the subpopulation model in which the total bacteria are assumed
to be a mixture of different populations is the adaptive resistance mechanism in which the
initial drug susceptible population is gradually considered to evolve into a drug resistant
population as shown in Figure 1-2C. Only one differential equation is used to describe
the rate of change of the total bacterial population. An adaptation factor (Į) is introduced
which may be dependent on time and concentration:
ߙ = 1 + ߚ × (1 െ ݁ ି×௧×ఛ )

Eq. 1-13

where ȕ describes the maximum adaptation factor and Ĳ represents the rate of adaptation.
Dependent on how the adaptation function is implemented in the PK/PD model, a gradual
increase in time and concentration may result in an increase in IC50 , decrease in Imax , or
decrease in bacterial replication rate [38].
Identification of the true resistance mechanism based only on total bacterial
counts and statistical modelling criteria have failed in the majority of cases.
Quantification of resistant populations will help in distinguishing between competing
models and support the selection of the most appropriate model for bacterial resistance
[39].
Inoculum Effect
The phenomenon that when a higher bacterial density of initial inoculum in an
experiment leads to a reduced antibacterial effect is referred to as inoculum effect [40]
Some of the potential mechanisms for this phenomenon are (i) enzymatic inactivation of
the drug, (ii) non-specific binding to the bacteria, and (iii) increased likelihood of the
preexistence of subpopulations of resistant bacteria if the density of the inoculum is
higher than the natural mutation rate of the bacteria. For example, the pharmacodynamic
HIIHFWRIFHIWD]LGLPHDȕ-lactam antibiotic, changed from time-dependent killing to
concentration-dependent killing when inoculum density was increased [41]. This
conversion in the PK/PD-index has bHHQOLQNHGWRWKHGLVWULEXWLRQDQGDFFXPXODWLRQRIȕODFWDPDVHLQWKHELRILOPRIKLJKGHQVLW\LQRFXODZKLFKFDQK\GURO\]Hȕ-lactam
antibiotics.
Bacterial burden shows a wide variation in patients and therefore a PK/PD model
which incorporates an inoculum effect might be more predictive in clinical scenarios.
One of the models proposed to describe inoculum effects is based on the concept of
quorum sensing. It assumes that all bacteria release signal molecules to communicate
with each other which consequently results in reduced drug sensitivity [42].
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Host Responses
,QYLYR models of bacterial infection are oftentimes established in immunocompromised animals as they allow for proper estimation of antibiotic efficacy without
any interference from the immune system. In many cases, the PK/PD indices needed to
be achieved for efficacy in these models are higher compared to those obtained in
immuno-competent animals [43]. ,QYLYR infection models in animals with functional
immune system, although less common, have also been used for assessing the efficacy of
antibiotics. As the immune system of immunocompetent animals has the ability to kill
bacteria, it is important to study the time course of this effect independently from
antibiotic therapy in order to be able to delineate the intrinsic activity of the drug from
that of the immune system. The immune system effect can be assessed by three different
approaches:
Modulation of bacterial challenge
In this approach inocula with different initial density were used in the same type
of animal infection model to quantify the antimicrobial effect associated with the immune
system [44]. The immune system was successful in reducing the bacterial load when the
initial inoculum was low; at higher initial inocula, however, the immune system’s
capacity was overwhelmed resulting in net bacterial growth. This impact of immune
system has been described quantitatively using mathematical models where the rate of
change in bacterial count is equal to the difference between the growth rate of bacteria
and the kill rate contributed by the antibacterial effect of the immune system [44]:
ௗே
ௗ௧

= ܭ௪௧ × ቀ1 െ

ே
ேೌೣ

ቁ×ܰെቀ

 ×ே

ேఱబ ାே

ቁ×ܰ

Eq. 1-14

Here, Kir is the maximal kill rate induced by the immune system and N50 is the number of
bacteria per g of tissue at which the immune-system mediated kill rate is half-maximal.
Modulation of immune reactivity
An alternative strategy to quantify the contribution of the immune system towards
bacterial reduction is to use animal infection models with different levels of
immunosuppression [45]. A pneumonia mouse model with functional immune system
was treated with different escalating doses of the immunosuppressant cyclophosphamide,
thereby reducing the neutrophil counts by 20, 70 and 90%, respectively. The rate of
change in the bacterial count was equal to the difference between the first order growth
rate of bacteria and the saturable kill rate attributed to the number of available
neutrophils:
ௗே
ௗ௧

= ܭ௪௧ × ቀ1 െ

ே
ேೌೣ

ቁ×ܰെቀ

 ×ே

ேఱబ ାே
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ቁ×ܰ

Eq. 1-15

ANC is the absolute neutrophil count and ANC50 is the ANC required to achieve 50% of
maximal kill rate.
Natural progression of disease
The effect of the immune system can also be included as a time-dependent firstorder kill rate, in addition to the natural death rate as described by Equation 1-16, for
example when immunocompetent animals are treated with vehicle control and establish
adaptive immunity over time. This assessment may result in a slight overestimation of the
impact of the immune system, however, if comparative data in immunocompetent and
immune-compromised animals are not available to delineate the real immune system
effect from natural bacterial death:
ௗே
ௗ௧

= ܭ × ቀ1 െ

ே
ேೌೣ

ቁ×ܰെቀ

 ×௧ ം
௧ఱబ ം ା ௧ ം

ቁ × ܰ െ ܭௗ௧ × ܰ

Eq. 1-16

Here Kir is the maximum death rate constant induced by the immune system, t is the time,
t50 is the time when the death rate constant is half of its maximum value, and Ȗ is the
sigmoidicity factor that determines the shape of the curve. The effect of the immune
system is thus modeled as a gradual, time-dependent increase of the death rate constant
until it reaches its maximum Kir .
Bench to Bedside Translation of PK/PD Models for Anti-Infectives
The current paradigm for translation of antibacterial PK/PD from preclinical
species to humans requires integration of the PK/PD index determined in animal models
with human pharmacokinetics [46]. Stochastic simulation of human drug exposure using
population pharmacokinetic models generates concentration-time profiles which are then
used to compute the PK/PD index for each simulated subject. Based on the proportion of
subjects with the desired value of the PK/PD index, probability of attaining the
therapeutic target is predicted. This approach helps in making decisions regarding the
choice of dosing regimens to be implemented in the clinic.
The use of mechanistic PK/PD models for translation from preclinical to clinical
scenarios has been limited. PK/PD models based on LQYLWUR static and dynamic kill
curves have been successful in the prediction of LQYLYR effects in animal models [9].
However, there is still a knowledge gap regarding translation of PK/PD parameters from
preclinical to clinical settings. For example, recently a multistate tuberculosis
pharmacometric model describing different bacterial states of 0\FREDFWHULXP
WXEHUFXORVLV was developed based on LQYLWUR data [4]. For clinical implementation of this
model [47], most of the parameters pertaining to the natural bacterial growth were fixed
to the LQYLWUR estimates; however the exposure-response parameters related to drug effect
had to be estimated from clinical data and were different from the LQYLWUR drug effect
parameters. More research efforts are needed in this area to better facilitate the
quantitative translation of mechanistic PK/PD models to clinical situations.
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Development of a Translational PK/PD Model for Antibiotics
Mechanism-based models for antibiotics are usually established in a stepwise
fashion, in which the different model components are individually developed and
integrated (Figure 1-3). The typical steps include the following:
1.

Development of a pharmacokinetic model in the studied population (animal
models or humans), that captures the time course of free, pharmacologically
active concentrations of the antibiotic, preferably in the relevant target tissue.

2.

Development of a bacterial growth model that captures the bacterial growth
kinetics and potential host response effects.

3.

Integration of the bacterial growth model and the pharmacokinetic model
component into a PK/PD model with a pharmacodynamic model component that
links the dynamics of drug concentrations to bacterial turnover. This may include
drug combination models, inocula effects, and resistance development.

Once the model has been established, it can be used for simulations to interpolate
and extrapolate the observed experimental data to other, untested scenarios, such as
different dosing regimens, or different patient populations [3, 48]. It can also be used for
quantitative comparisons of multiple drug candidates to identify lead candidates and
support go-no go decisions [8].
Conclusions
Mechanism-based PK/PD models are increasingly been used in developing dosing
strategies for antibiotics in drug development and clinical application. Although these
models are simplified depictions of rather complex interactions of drug, microbe and host
physiologic processes, they are able to capture the time course and magnitude of
antibacterial effect in relation to bacterial growth, the pharmacokinetic and
pharmacodynamic properties of the drug, and the chosen dosing regimen. Complicating
factors such as resistance development, combination therapy, or host responses can be
incorporated in the modeling approach. In situations where only limited data are
available, system specific parameters describing for example growth characteristics may
also be implemented based on prior knowledge [4]. With these tools at hand, translational
PK/PD modeling and simulation may play a pivotal role in identifying the right balance
between bacterial killing, adverse effects, and appearance of resistance, and may help
identifying and optimizing dosing regimens for novel and established antibacterial
agents.
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Figure 1-3.

Steps involved in the development and application of a translational PK/PD model for antibiotics
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CHAPTER 2. HYPOTHESIS AND SPECIFIC AIMS
Tuberculosis (TB) is a serious life threatening disease resulting in 1.4 million
deaths per year. Multidrug resistant (MDR) TB (resistant to first line agents: Rifampin
and Isoniazid) causes an estimated 300,000 deaths per year. To further exacerbate the
situation, extensively drug resistant (XDR) TB (resistant to first line agents and at least
one second line agent) and totally drug resistant TB (resistant to all first and second line
agents) infections are increasing at an alarming rate in the developing world.
The devastating socioeconomic and public health impact of tuberculosis and the
known toxicity of many existing treatments motivated our research team to develop
spectinamides, a series of semi-synthetic analogues of the antibiotic spectinomycin, into a
novel class of antitubercular drugs. Spectinomycin historically has been used as a secondline agent to treat gonorrheal infections; however, it has only limited activity against
0\FREDFWHULXPWXEHUFXORVLV (0WE). Yet, its high safety margin and its distinct ribosomal
binding site make it a preferred lead structure. By modifying its structure, our research
team generated spectinomycin analogues with excellent LQYLYR antitubercular activity
which bind to a unique site within the 30S mycobacterial ribosome subunit, and block
ribosome translocation. Furthermore, it was also demonstrated that spectinamides, in
spite of being highly hydrophilic, are extremely efficacious because in contrast to
spectinomycin they are able to evade the efflux transporter Rv1258c expressed in 0WE.
These findings for the first time challenged the previous view in the field that 0WE is
intrinsically resistant to many polar antibiotics because of its waxy coating around the
cell membrane.
Spectinamides have undergone a comprehensive lead optimization process which
included refining the chemical structure to obtain optimum pharmacological,
biopharmaceutic and pharmacokinetic characteristics using an iterative approach. Based
on these evaluations, Lee 1599 and Lee 1810 have emerged as lead candidates with
excellent antitubercular activity against both drug susceptible as well as MDR- and XDRdrug resistant 0WE strains, a high safety margin, narrow anti-microbial spectrum, lack of
cross-resistance with other protein synthesis inhibitor, low synthesis cost, and favorable
pharmacokinetic characteristics. The overall objective of my dissertation work is to
utilize translational PK/PD approaches for the further advancement of spectinamide lead
candidates, Lee 1599 and Lee 1810, into the late discovery stage. I hypothesize that
translational PK/PD approaches facilitate the drug development process in the late
discovery stage by providing information on optimal dose selection, rationales for routespecific efficacy differences, and the feasibility of reaching efficacious drug exposures in
humans.
Specific Aim 1
Identifying the main driver for antibiotic efficacy is essential for designing its
optimum dosing schedules. In Specific Aim 1 (Chapter 3), I hypothesize that the LQYLYR
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anti-mycobacterial activity of Lee 1810 follows a defined dose-exposure-response
relationship. In order to prove this hypothesis and characterize the dose-exposure and
exposure-response relationships for Lee 1810, I will develop a semi-mechanistic PK/PD
modeling approach and apply it on concentration and efficacy data obtained from a dose
fractionation study in a mouse model of chronic 0WE infection.
Specific Aim 2
Spectinamides are highly water soluble and poorly permeable resulting in limited
oral bioavailability; hence are usually administered through the subcutaneous route in
mice. Since lungs are the main site of infection in pulmonary TB, the efficacy of lead
spectinamide Lee 1599 was also evaluated after intratracheal administration in a mouse
model of 0WE infection. Intratracheal administration of lead spectinamide Lee 1599 was
shown to be significantly more efficacious than subcutaneous administration at
comparable doses. In Specific Aim 2 (Chapter 4), I hypothesize that this higher efficacy
is caused by a higher exposure of Lee 1599 to the target organ, the lungs, after
intratracheal compared to subcutaneous administration. I address this hypothesis in a
comparative biodistribution assessment of Lee 1599 after subcutaneous and intratracheal
administration in mice.
Specific Aim 3
The translation from the preclinical stage to the clinical stage is one of the most
critical steps in a drug development program as it requires extrapolation of results for
efficacy, safety, PK/PD and toxicology from preclinical species to humans.
Physiologically-based pharmacokinetic (PBPK) modeling and simulation is one of the
powerful methodologies which is increasingly used for predicting drug exposure in
humans based on the pharmacokinetic behavior observed in preclinical species. In
Specific Aim 3 (Chapter 5), I hypothesize that systemic exposures to Lee 1599 found to
be efficacious in mice are also feasible to be reached in humans. I address this hypothesis
by developing and applying a PBPK model for Lee 1599 to predict pharmacokinetics and
dose requirements of Lee 1599 in humans. This includes the development of a PBPK
model for describing the pharmacokinetics of Lee 1599 in rats and mice, and the
subsequent use of the model for prediction of human pharmacokinetics of lead
spectinamide Lee 1599.
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CHAPTER 3. DOSE-EXPOSURE-RESPONSE ANALYSIS OF
SPECTINAMIDE ANTIBIOTIC LEE 1810 IN 0<&2%$&7(5,80
78%(5&8/26,6 INFECTED MICE
Introduction
Tuberculosis (TB) is a serious life-threatening disease resulting in 1.4 million
deaths per year [49]. Multidrug-resistant (MDR) TB (resistant to the first line agents
rifampin and isoniazid) causes an estimated 300,000 deaths per year [50]. To make
matters worse, extensively drug-resistant (XDR) TB (resistant to first line agents and at
least one second line agent) and totally drug-resistant TB (resistant to all first and second
line agents) infections are increasing at an alarming rate in the developing world. To
address the increasing prevalence of MDR and XDR infections, several novel scaffolds
of antibiotics are currently being investigated in various stages of pre-clinical and clinical
development [51].
Our research group has recently discovered novel antitubercular agents known as
spectinamides. Spectinamides are semi-synthetic derivatives of spectinomycin, an
aminocyclitol that inhibits bacterial protein synthesis by binding to a site within the
bacterial 30S ribosome (helix 34 of 16SrRNA) distinct from that of other protein
synthesis inhibitors. This property provides the necessary selectivity, narrow spectrum
antitubercular activity and lack of cross-resistance with other antibiotics. In multiple
murine infection models, spectinamides were successful in significantly reducing lung
mycobacterial burden and also improving survival. Unlike aminoglycosides,
spectinamides do not inhibit human mitochondrial translation and do not exhibit offtarget effects which are linked to aminoglycosides-related ototoxicity [52].
Based upon LQYLWUR screening assays, pharmacokinetic studies, and preliminary LQ
YLYR efficacy studies in rodents, Lee 1810 emerged as one of the lead candidate molecules
from the class of synthesized spectinamide compounds. Lee 1810 has a minimum
inhibitory cRQFHQWUDWLRQ 0,& RIȝJP/ [53], a favorable pharmacokinetic profile
with high microsomal metabolic stability and renal excretion as the primary elimination
pathway. In mouse models of chronic 0\FREDFWHULXPWXEHUFXORVLV (0WE) infection, Lee
1810 monotherapy reduced the lung bacterial load comparable to streptomycin.
Given the long cycle time involved in new drug development coupled with the
limited pipeline of antitubercular agents under development, it is essential to use novel
antibiotics for this indication in the most appropriate way. To maximize efficacy, and
minimize toxicity and emergence of resistance associated with spectinamides, it is critical
to use optimum dosing strategies which are based upon pharmacokinetic
/pharmacodynamic (PK/PD) principles. The main objective of the work summarized in
this chapter is to develop a semi-mechanistic PK/PD model to characterize the doseexposure-response of lead spectinamide Lee 1810 based on a dose-fractionation study in
a mouse model of chronic 0WE infection. The PK/PD relationship established in this
model will further support dose selection in preclinical development and will eventually
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facilitate translation of preclinical information to humans by informing clinical trial
designs and determining clinically optimum dosing regimens.
Materials and Methods
Chemicals and reagents
Spectinamide antibiotic Lee 1810 (2-(5-hydroxypyridin-2-yl)-N((2R,4R,4aS,5aR,6S,7S,8R,9S,9aR,10aS) -4a,7,9-trihydroxy-2-methyl-6,8bis(methylamino)decahydro-2H-benzo[b]pyrano[2,3-e][1,4]dioxin-4-yl)acetamide) as
shown in Figure 3-1 was synthesized in Dr. Richard E. Lee’s Lab at St. Jude Children’s
Research Hospital, Memphis, TN as previously described [54]. Acetonitrile, methanol,
HPLC grade water, formic acid and nonafluoropentanoic were purchased from Fisher
Scientific (Pittsburgh, PA). Drug free BALB/c mouse plasma was purchased from
Innovative Research (Novi, MI).
Dose-fractionation study in a chronic mouse model of 0WE
6-8 week old BALB/c female mice (150 total) were infected with 0WE Erdman
with a Low Dose Aerosol (LDA) infection as previously described [49], using an
inoculum concentration of 2.0×106 CFU/ml to achieve deposition of ~100 CFU in the
lungs for the BALB/c mice. At Day 34 post infection, subcutaneous (SC) administration
with Lee 1810 was initiated with different dosing regimens as described in Table 3-1 and
continued for 4 weeks with drug holidays on weekends. The spectinamides were
formulated in Plasma-Lyte (Baxter, Deerfield, IL) and water with different ratios for each
group in order to maintain ideal osmotolerance close to physiological values, and 0.2 ml
of the formulation was administered subcutaneously using a 29 gauge insulin syringe. To
assess the pharmacokinetics of Lee 1810 under multiple dosing in infected mice, two
blood samples were taken per mice by submandibular bleed collected in BD Microtainer
plasma separator tubes containing lithium-heparin (BD, Franklin Lakes, NJ): one at 0.25
h post SC administration (C0.25) and another at the 8 h post SC administration during the
last week of dosing (C8). Plasma was separated immediately by centrifugation (10,000g
IRUPLQDW& DQGVWRUHGDWí&XQWLODQDO\VLV$IWHUZHeks of treatment
followed by 2 days of washout period, lungs were harvested and homogenized for
dilution and plated on Middlebrook 7H11 agar plates supplemented with oleic acidalbumin-dextrose-catalase (OADC). Plates were incubated at 37°C and colonies (CFU)
were enumerated after at least 21 days of incubation. To enumerate the bacterial uptake
from the LDA infection, 6 BALB/c mice were sacrificed day 1 post-infection. On Day 34
post-infection, 5 BALB/c mice were sacrificed to determine bacterial load at the start of
therapy. On Day 62 post-infection, 5 BALB/c untreated mice and 7 BALB/c mice dosed
with vehicle were sacrificed to determine bacterial load in the untreated group and
placebo group respectively. This information was used for describing the natural bacterial
growth. The viable CFU counts were logarithmically converted for further data analysis.
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Figure 3-1.

Structure of Lee 1810
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Table 3-1.

Dosing regimens evaluated in the dose-fractionation study

Dosing
frequency 20
5x per
week
(m-f)
twice
5x per
week
(m-f)
3x per
week
(m,w,f)
2x per
week
(m,r)
20
1x per
QW
week (m)

40

60

80

100
10
BID

120

20
QD
20
TIW
20
BIW
40
QW

Total weekly dose (mg/kg)
200 300 400 500 600
20
50
BID
BID
40
QD

40
TIW
40
BIW

100
QD
100
TIW

100
BIW

1000 1200 2000 3000 4000
100
200 300 400
BID
BID BID BID
200
QD

200
TIW

400
QD

600
QD

400
TIW

200
BIW

100
QW

Abbreviations: m, Monday; t, Tuesday; w, Wednesday; r, Thursday; f, Friday; BID, Twice daily; QD, Once daily; TIW, Thrice
weekly; BIW, Twice weekly; QW, Once weekly.
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The dose-fractionation study was conducted in the dedicated BSL-3 facility by the
research group of Dr. Anne Lenaerts at Colorado State University according to the
guidelines of the Colorado State University Institutional Animal Care and Use
Committee. As the plasma samples were collected from 0WE infected mice, it was
neceVVDU\WRVWHULOL]HWKHPEHIRUHELRDQDO\VLV$YDOLGDWHGDSSURDFKZLWKȖ-irradiation at
a radiation dose of 1 Mrad using a Cobalt-60 gamma irradiator was used for sterilization
of the plasma samples. To account for degradation of drug during the irradiation process,
quality control samples of known concentrations (10 ng/mL (low), 1 μg/mL (medium),
and 10 μg/mL (high)) were simultaneously irradiated. After sterilization, the sample
concentrations were quantified and the concentrations were corrected for the drug lost
during the irradiation procedure.
Pharmacokinetic study in healthy mice
To assess the pharmacokinetics in healthy compared to infected mice and to
provide an anchor point for a population pharmacokinetic analysis of the limited samples
obtained in the mouse model of chronic 0WE infection, female BALB/c mice (6–8 weeks
old, ~20 g, n = 15) were dosed with 200 mg/kg of Lee 1810 subcutaneously. Blood
samples were collected at 0.083, 0.25, 0.5, 1, 2, 3, 5, 8, 12 and 24 h after administration.
Each mouse provided two blood samples, one by a one-time retro-orbital bleed under
isoflurane anesthesia and the other by cardiac puncture under isoflurane anesthesia
followed by euthanasia through cervical dislocation. This pharmacokinetic study was
performed at the University of Tennessee Health Science Center following approval by
the Institutional Animal Care and Use Committee. Plasma was separated immediately by
FHQWULIXJDWLRQDVGHVFULEHGDERYHDQGVWRUHGDWí&XQWLO/&-MS/MS analysis.
Quantification of Lee 1810 concentrations in plasma
7KHSODVPDVDPSOHVZHUHSURFHVVHGE\SURWHLQSUHFLSLWDWLRQ7Rȝ/DOLTXRWV of
specimens ȝ/PHWKDQROFRQWDLQLQJWKHLQWHUQDOVWDQGDUG/HH ƍ-dihydro-ƍdeoxy-ƍ 5 -isopropylacetylamino spectinomycin) was added. This was followed by
vortexeing for 1 min and centrifugation at 10,000g for 10 min at 4oC. The supernatant
was VHSDUDWHGDQGȝ/RIVXSHUQDWDQWZDVDQDO\]HGXVLQJKLJK-performance liquid
chromatography coupled with tandem mass spectrometry (LC-MS/MS).
Chromatographic separations were carried out using a Shimadzu Nexera XR (LC20ADXR) liquid chromatograph (Shimadzu Corporation, Kyoto, Japan) consisting of two
pumps, online degasser, system controller and an autosampler. Liquid chromatography
ZDVSHUIRUPHGRQ:DWHUV6\PPHWU\ȝP&îPPFROXPQ :DWHUV
Milford, MA). The mobile phase was solvent A (water with 1.6% nonafluoropentanoic
acid and 0.7 % formic acid) and solvent B (90% acetonitrile with 0.8%
nonafluoropentanoic acid and 0.35% formic acid) in the gradient mode as follows: 0–0.5
min, 20% B; 0.5–1.6 min, 20–90% B; 1.6–2 min, 90% B; 2-2.5 min, 90-20% B, 2.5–3
min, 20% B at a flow rate of 0.5 mL/min. Analytes were detected with a API 5500 triplequadruple mass spectrometer (Applied Biosystems, Foster City, CA) with electrospray
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ionization in multiple reaction monitoring mode using the compound-specific mass
transfers of m/z 469.2/ 207.1 for Lee 1810 and m/z 418.3/207.1 for Lee 1369.
Two calibration curves ranging from 1.95 to 2,000 ng/mL and 1.95 to 1000
μg/mL were constructed and validated with spiked samples of mouse plasma. Samples
with concentrations above 2000 ng/mL were analyzed with the higher calibration range.
The peak area ratios of analyte to internal standard was linear over the concentration
range tested for both compounds, with correlation coefficients (weighted least-square
linear regression analyses) >0.997. Accuracy (deviation of the analyzed quality control
samples from nominal values) was within ±3% over the entire range of the calibration
curve, and precision (coefficient of variation of repeated measurements of the quality
control samples) was <2%.
Dose proportionality assessment
The assessment of dose linearity and dose proportionality was performed by
power regression modeling on log-transformed data for C0.25 and C8. 95% confidence
intervals for the slopes were determined from the power regression analysis. The dose
SURSRUWLRQDOLW\ZDVFRQVLGHUHGOLQHDUZKHQWKHORZHUFRQILGHQFHOLPLWVZHUHDQG
XSSHUFRQILGHQFHOLPLWVZHUH[55].
Population pharmacokinetic model development
A population pharmacokinetic model was used to simultaneously describe the
plasma concentration measurements from both healthy and infected mice by nonlinear
mixed-effects modeling. The concentration data were natural log transformed and
modeled using a log-transform-both-sides (LTBS) approach [56]. The evaluation of the
structural pharmacokinetic model was undertaken by visual exploratory data analysis.
The densely sampled concentration-time points in the healthy mice were primarily used
to guide base model development. Once the base model could adequately describe the
data in healthy mice with physiologically plausible parameter estimates, the model was
expanded to include the sparse pharmacokinetic data from the dose-fractionation study.
Based upon the biphasic distribution of Lee 1810 after SC administration, a twocompartment model with first-order absorption was used to describe the
pharmacokinetics of Lee 1810 (Figure 3-2).
For all models evaluated in this population analysis, between-subject variability
(BSV) was modeled as a log-normal distribution,
ܲ = ܲ × ݁ ఎ

Eq. 3-1

where Pi is the parameter estimate for mouse i, Ppop represents the typical population
value for the parameter, and Și is the independent random variable in mouse i, described
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Figure 3-2. Two-compartment pharmacokinetic model for characterizing the
pharmacokinetics of Lee 1810
Abbreviations: C, concentration in the central compartment; CP, concentration in the
peripheral compartment; Q/F, intercompartmental clearance corrected for bioavailability;
CL/F, clearance corrected for bioavailability; Ka , first-order absorption rate constant.
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by a normal distribution with mean zero and variance Ȧ2 , which corresponds to a lognormal distribution for the parameter.
The residual unexplained variability (RUV) was characterized as an additive
error, which relates to a proportional error when using an LTBS approach, such that:
ܥ(݊ܮ ) = ݊ܮ൫ + ൯ + ߝ

Eq. 3-2

where Ln൫Cij ൯ is the natural logarithm of the jth observed concentration in the mouse i,
Ln൫Ƙij ൯ is the natural logarithm of the model predicted concentration for the jth
observation in the mouse i, and İij is the residual error characterized by normal
distribution with mean zero and variance ı2 .
Following the development of the base model, disease effect was tested as a
categorical covariate coded as power model on clearance (CL/F), central volume of
distribution (Vc /F) and intercompartmental clearance (Q/F) using the following
relationship:
ܲ = ߠଵ × (ߠଶ )ௌ௧௧௨௦

Eq. 3-3

where P represents the typical value of parameter in the population, Status is an indicator
variable equal to 0 for healthy mice and 1 for infected mice, ș1 is the typical value of P
for healthy mice, and ș2 is the multiplicative factor describing the increase or decrease in
P as a result of the infection.
To account for the more than dose-proportional increase in C0.25 above doses of
100 mg/kg as observed in the data, a higher absorption rate for these groups was tested
using the following relationship:
ܲܭ = ߠଷ × (ߠସ )ு

Eq. 3-4

where PopKa represents the typical value of Ka in the population, HD is an indicator
YDULDEOHHTXDOWRIRUGRVHPJNJDQGIRUGRVH!PJNJș3 is the typical
value of Ka IRUGRVHPJNJDQGș4 is the multiplicative factor describing the
increase in Ka for dose >100 mg/kg.
Semi-mechanistic PK/PD model development
The semi-mechanistic PK/PD model developed to describe the effect of Lee 1810
on 0WE in the murine infection model takes into consideration the time course of bacterial
count based on LQYLYR information. The model was composed of three basic components:
(i) a component that describes the bacterial growth kinetics, (ii) a component that
describes the pharmacokinetics of Lee 1810, and (iii) a component that integrates the
effect of the drug concentration on bacterial turnover.
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The natural bacterial growth of 0WE in the control group of untreated
immunocompetent mice was characterized based on time courses of CFU data obtained
from this study, previously performed studies by Dr. Anne Lenaerts’ research group at
Colorado State University using the same mouse and bacterial strains, and from the
scientific literature (Figure 3-3) [57-59]. The growth kinetics in untreated groups of mice
was found to be independent of the bacterial or mouse strain used in the study (Table
3-2). This is consistent with the observations made previously where mice infected
intravenously or aerogenically with 0WE strains of CDC 1551, Erdman, H37Rv developed
almost identical infections in the lungs and spleen [60].
The model for natural mycobacterial growth in the untreated group of
immunocompetent mice was developed by implementing the idea of phenotypic
heterogeneity, where a fast growing bacterial population (N1 ) switches into a slow
growing population (N2 ) as a result of stochastic or induced expression of persister genes
as shown in Figure 3-4 [61]. The implementation of this model was inspired from the 2subpopulation approach used for describing the LQYLWUR growth kinetics of 6WUHSWRFRFFXV
S\RJHQHV [17]. In the early exponential growth phase, N1 is assumed to constitute the
majority of total bacteria with a first-order replication rate of Krep .The conversion from
the fast growing stage to the slow growing stage was assumed to be triggered by a high
total bacterial population. In the model, the N2 have the ability to revert back to the fast
growing bacteria once the conditions become favorable. However, during initial model
evaluation, the transfer from N2 to N1 was negligible and was therefore fixed to 0 in
further model development. The mice used in the dose-fractionation study were
immunocompetent. Interferon-ȖSURGXFLQJ7-cells, which regulate the adaptive immune
system, are recruited to the lungs post-infection in aerosol infected mouse models [59]. In
order to account for the role of host immune reaction in killing bacteria, a first-order
death rate constant Kir was introduced on both bacterial subpopulations. The CFU
readout from the agar plates was considered to represent the sum of both bacterial
subpopulations. The initial number of bacteria in the fast growing subpopulation (N1, 0 )in
the starting inoculum was estimated during the model fit. Since the mice were challenged
with a low-dose aerosol inoculum of bacteria in the early logarithmic phase, the initial
number of N2 was fixed to 0.
ௗேభ
ௗ௧
ௗேమ
ௗ௧

= ܭ × ܰଵ െ ܭ × ܰଵ െ (ܭ െ ܭ ) × ቀ
= (ܭ െ ܭ ) × ቀ

ேభ ାேమ
ேೌೣ

ቁ × ܰଵ െ ܭ × ܰଶ

ேభ ାேమ
ேೌೣ

ቁ × ܰଵ

Eq. 3-5
Eq. 3-6

Once the natural bacterial growth model had been developed, the next step was to
integrate it with the drug effect. Based on the individual SRVWKRF estimates from the
population pharmacokinetic modeling, a sequential PK/PD analysis was performed by
linking the pharmacokinetic model with the bacterial growth model via an exposuredependent kill function associated with the effect of Lee 1810 as shown in Figure 3-5.
The parameters related to the natural bacterial growth model were fixed during the drug
evaluation and only the drug effect parameters were estimated during the PK/PD
analysis.
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Figure 3-3.
Natural bacterial growth of 0\FREDFWHULXPWXEHUFXORVLV in the
untreated group of immunocompetent mice
Dunphy HWDO [58], Rifat HWDO [57], Tischler HWDO [59] and US Patent 7722861B2 [62]
represents the literature sources from which the data was extracted. CSU_1 represents the
data obtained from the current dose fractionation study of Lee1810 and CSU_2, CSU_3
and CSU_4 are the time courses of CFU data obtained from previously performed studies
by Dr. Anne Lenaert’s research group at Colorado State University using the same mouse
and bacterial strains.
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Table 3-2.
Information about the bacterial and mouse strain reported in the
literature sources from which the data was extracted for the natural bacterial
growth of 0\FREDFWHULXPWXEHUFXORVLV in the untreated group of immunocompetent
mice
Literature source
Bacterial strain Mouse strain
Dunphy HWDO
H37Rv
C57BL/6
Rifat HWDO
CDC1551
BALB/c
Tischler HWDO
Erdman
C57BL/6
US Patent 7722861B2
H37Rv
C57BL/6
CSU_1, _2, _3, _4
Erdman
BALB/c
Dunphy HWDO [58], Rifat HWDO [57], Tischler HWDO [59] and US Patent 7722861B2 [62]
represents the literature sources from which the data was extracted. CSU_1 represents the
data obtained from the current dose fractionation study of Lee1810 and CSU_2, CSU_3
and CSU_4 are the time courses of CFU data obtained from previously performed studies
by Dr. Anne Lenaerts’ research group at Colorado State University using the same mouse
and bacterial strains.
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Figure 3-4.

Two-subpopulation 0\FREDFWHULXPWXEHUFXORVLV growth model

Abbreviations: N1 , cell count of fast growing population; N2 , cell count of slow growing
population; Krep , first-order replication rate constant; Nmax , maximum number of bacteria;
Kir , first-order death rate constant induced by the immune reaction.
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Figure 3-5. PK/PD model of Lee 1810 consisting of a two-compartment pharmacokinetic model and 0\FREDFWHULXP
WXEHUFXORVLVgrowth model integrated with additive drug effect
Abbreviations: N1 , cell count of fast growing population; N2 , cell count of slow growing population; Krep , first-order replication rate
constant; Nmax , maximum number of bacteria; Kir , first-order death rate constant induced by the immune reaction; Emax , maximum kill
rate induced by Lee1810; C, is concentration of Lee 1810 at time t; EC50 , concentration of Lee1810 at half of Emax and Ȗ is the
sigmoidicity factor.
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The drug effect was evaluated as an additive effect. The additive model describes
the drug effect as an additional kill rate as described by Equation 3-7.
ௗேభ
ௗ௧

= ܭ × ܰଵ െ ܭ × ܰଵ െ (ܭ െ ܭ ) × ቀ

ேభ ାேమ
ேೌೣ

ቁ × ܰଵ െ ൬

ாೌೣ × ം
ം

 ം ା ாఱబ

൰ܰכ

Eq. 3-7

In the Equation 3-7 and Figure 3-4, the effect corresponds to an additional kill-rate
constant contributed by the drug with Emax representing the maximum achievable drugimposed kill-rate constant having the unit 1/time and Ȗ is the sigmoidicity factor, which
determines the shape of the concentration-effect relationship.
The CFU data were log transformed by taking Log base 10 to Log CFU. Similar
to the pharmacokinetic analysis, a LTBS approach was also used for the PK/PD model,
and the unexplained residual variability was characterized using as an additive error. As a
single sample was available per animal, it was not feasible to separately estimate BSV
and residual variability [63]; hence only the RUV characterized as additive error was
estimated in the model.
Model qualification
In order to comprehensively characterize the dose-exposure-response relationship
for Lee 1810, the adequacy of the developed semi-mechanistic PK/PD model was
evaluated by performing a Visual Predictive Check (VPC) in which the parameters
derived from the final model were used to simulate data and compare them for their
consistency with the observed data [64]. Monte Carlo simulation was performed with a
total of 1000 replicates to obtain the dose-response curves ranging from weekly dose of 0
mg/kg to 5000 mg/kg with QW, BIW, TIW, QD and BID. The primary endpoint here
was the bacterial count at the end of drug treatment. The median value of simulations was
plotted as a line while the 80%, 70% and 60% prediction intervals were represented as
pink, purple and green shaded bands respectively.
Numerical simulations for the two subpopulations
The extent of change in each of the bacterial subpopulation was simulated based
on the final PK/PD model for all the groups tested in this study. This simulation provides
an overview of the quantitative dynamics in bacterial population growth with different
dosing regimens
Data analysis and software
The PK/PD data analysis and simulations were performed in the nonlinear mixed
effects modeling software NONMEM (version VII, level 2.0; Icon, Hanover, MD) using
the first-order conditional estimation (FOCE). The software suite R (version 3.2; R
Foundation for Statistical Computing) was used for data management and graphical as
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well as statistical assessment of models. Models were evaluated based on goodness-of-fit
plots, objective function value, parameter precision and scientific plausibility. Model
comparison for hierarchical models was performed using the likelihood ratio test. The
differences in the objective function value are approximately Chi-square distributed with
n degrees of freedom (n is the difference in the number or parameters between the full
and the reduced model). The differences in objective function of 3.84 for 1 degree of
freedom, corresponding to a significance level of p < 0.05, was used to discriminate two
hierarchical models.
Results and Discussion
The overall goal of this study was to characterize the dose-exposure-response
relationship of lead spectinamide candidate Lee 1810 in 0WE infected mice using a
PK/PD modelling approach. In order to separately tease out the impact of dose and
dosing regimen on the response, a dose-fractionation study was conducted over a wide
range of weekly doses, including 20-4000 mg/kg using different dosing frequencies.
There were in total 24 dose groups with 5 mice per group (except for groups of Day 1
post-infection with 6 mice, Day 34 post-infection with 5 mice and Day 62 post-infection
with 7 mice). BALB/c mice were infected with a low dose aerosol of 0WE, followed by a
gap of 5 weeks to allow infection to establish and subsequently treated with different
dosing regimens of Lee 1810 as described in Table 3-1. Dosing was continued for 4
weeks with 2 blood samples at 0.25 h and 8 h from each mice in the last week, followed
by a washout period after which the mice were sacrificed, and the lungs removed for
measurement of CFU. The study was successfully completed in 116 mice, resulting in
226 concentration measurements and 116 lung CFU measurements. 4 were lost during
the conduct of the study for non-drug related issues.
Dose proportionality
The concentrations at 0.25 h and 8 h increased consistently with increase in dose
as shown in Figure 3-6. For the same dose level, the concentrations at 0.25 h and 8 h
were similar for different dosing frequencies suggesting minimal accumulation. Dose
proportionality was evaluated by using the power regression model on the logtransformed data for C0.25 and C8 across the dose range evaluated in the dosefractionation study. Plots of log-transformed C0.25 and C8 along with the regression lines
are displayed in Figure 3-7. Results from the power regression analysis of the C0.25 and
C8 are summarized in Table 3-3.The concentrations at C0.25 increased in a doseproportional fashion until 100 mg/kg, and were more than dose-proportional between 200
– 400 mg/kg. However, concentrations at C8 were found to be dose-proportional across
the entire dose range. The more than dose-proportional increase observed in C0.25 above
the dose of 100 mg/kg may be caused by an increased absorption rate associated with
faster diffusion at the subcutaneous site of administration at higher concentrations. This
information was useful for characterizing the nonlinearity for the subsequently developed
population pharmacokinetic model.
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Figure 3-6. Concentration of Lee 1810 at 0.25 h (top panel) and 8 h (bottom
panel) for the different dosing regimens evaluated in the dose-fractionation study
Each column heading represents the amount of single dose in mg/kg. The open black
circles indicate observed data, red points indicate the mean and blue lines indicate the
standard error of the observed data.
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Figure 3-7. Dose proportionality assessment of C0.25 (top panel with concentration
units in μg/mL) for a dose range of 10 - 100 mg/kg and C8 (bottom panel with
concentration units in ng/mL) for a dose range of 10 - 400 mg/kg
The blue line represents the regression line and red open circles represent the observed
data.
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Table 3-3.

Dose proportionality test using power regression model for Lee 1810.
Parameter
C0.25
C0.25
C8

95% confidence limit
Dose range
Slope
(mg/kg)
Lower
Upper
10 - 400
1.19
1.10
1.27
10 - 100
1.08
0.92
1.24
10 - 400
0.918
0.792
1.04
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Population pharmacokinetic analysis of Lee 1810
The population pharmacokinetic modeling approach has been extensively used for
characterizing preclinical and clinical pharmacokinetics especially in cases involving
sparse sampling per individual/animal [65]. The non-linear mixed effects modeling
approach was successfully applied for simultaneous modeling of the pharmacokinetics of
Lee 1810 in healthy mice with intensive pharmacokinetic data as shown in Figure 3-8
and in infected mice with sparse sampling data. A two-compartment model with firstorder absorption and linear elimination from the central compartment was used to
characterize the plasma concentration–time profile of Lee 1810 (Figure 3-9). The model
was parameterized in terms of first-order absorption rate constant (Ka ), clearance (CL/F),
central volume of distribution (Vc /F), inter-compartmental clearance (Q/F) and peripheral
volume of distribution (Vp /F). The parameter estimates along with their precision are
given in Table 3-4. The drug undergoes rapid absorption from the subcutaneous site with
an absorption rate constant of 2.31 h-1, which corresponds to a short absorption half-life
of 18 min. Lee 1810 displayed a biphasic pharmacokinetic profile with its volume of
distribution mainly limited to the extracellular fluid volume with some peripheral
distribution. Similar to other cationic amphiphilic drugs, Lee 1810 may also have high
binding affinity towards intracellular phospholipids, and slow release from these sites
could be the potential reason for its prolonged terminal elimination half-life [66].
To account for the potentially increased absorption above the dose of 100 mg/kg,
a separate absorption rate was included for these groups, which resulted in a significant
drop in the objective value functLRQ ¨2%- - 8.99).The groups with doses above 100
mg/kg had a mean absorption rate of 5.89 h-1 which was ~2.5-times higher than the mean
absorption rate of 2.31 h-1 for groups with doses less than 100 mg/kg.
Health status as a covariate on Vc /F, CL/F and Q/F improved model fits and
UHVXOWHGLQDVLJQLILFDQWGURSLQREMHFWLYHYDOXHIXQFWLRQ ¨2%- - 7.38 for Vc /F ¨2%-
= - 7.00 for CL/F DQG¨2%- - 12.8 for Q/F). The pharmacokinetics were found to be
different between healthy and infected mice with the later having a 56.5% lower CL/F,
69% lower Vc /F and 69.6% lower Q/F The reason for the reduced clearance is not clear,
particularly since Lee 1810 is largely eliminated by renal excretion without major
metabolic conversion. A 2.5- to 3-fold lower clearance, however, was also observed with
dihydrostreptomycin in TB infected mice as compared to healthy mice [67]. In some
human patient populations, reduced clearance has also been observed for rifampin [68],
which is typically known to exhibit increased clearance due to autoinduction during
chronic therapy [69]. One of the potential explanations for lower CL/F in infected mice
could be an alteration in protein binding of Lee1810. Lee 1810 is a basic drug and is
found to have a protein binding of 40% in rat plasma. With its two ionizable basic
moLHWLHV/HHFRXOGSRVVLEO\ELQGWRĮDFLGJO\FRSURWHLQ $$* ZKLFKLVDQDFXWHphase plasma protein that predominantly binds to basic drugs and increases in reaction to
bacterial infections and other inflammatory stimuli [70]. For example, the plasma AAG
concentration was found to be significantly higher in patients with plasmodium filarial
malaria infection as compared to healthy individuals, resulting in a lower free fraction of
antimalarial drug quinine [71]. Additionally, patients with Crohn’s disease, inflammatory
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Figure 3-8. Concentration–time profile of Lee 1810 for a single dose of 200 mg/kg
by subcutaneous administration in healthy BALB/c mice
The red line indicate the population prediction, black points indicate the mean and the
blue error bars indicate the standard error of the observed data at each time point (n=3).
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Concentration (μg/mL)

Time (Day)

Figure 3-9. Individual Lee 1810 concentration-time profiles for the different treatment groups tested in the dosefractionation study
The observed concentrations (open black circles) and population predictions (thick red line) are depicted for the time period of 56 to
60 days after initiation of infection (equivalent to 22 to 26 after initiation of dosing).
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Table 3-4.

Population pharmacokinetic model parameter estimates
Typical value
%BSV
(%RSE)
(%RSE)
2.31 (17.8)
Ka (h-1)
0.435 (21.6)
Vc /F (L/kg)
Vp /F (L/kg)
0.161 (22.2)
1.17 (9.30)
19.9 (53.7)
CL/F (L/h/kg)
0.0191 (21.5)
Q/F (L/h/kg)
Effect of disease on CL/F 0.435 (19.5)
0.310 (24.2)
Effect of disease on Vc /F
0.304 (29.3)
Effect of disease on Q/F
5.89 (15.8)
Ka > 100mg/kg
RUV(%CV)
49.3 (7.3)
Parameters

Abbreviations: Ka , absorption rate constant; Vc /F, volume of central compartment
corrected for bioavailability; Vp /F, volume of peripheral compartment corrected for
bioavailability; CL/F, clearance corrected for bioavailability; Q/F, intercompartmental
clearance corrected for bioavailability; Effect of disease on parameter was determined
using the following relationship: P=ș1 × ș2 )Status , where P represents the typical value of
parameter in the population, Status is an indicator variable equal to 0 for healthy mice
and 1 for infected mice, ș1 is the typical value of P for healthy mice, and ș2 is the
multiplicative factor describing the increase or decrease in P as a result of the infection
; Ka > 100 mg/kg, absorption rate constant for dose above 100 mg/kg; RUV, Residual
Unexplained Variability
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arthritis, and chronic renal failure also had increased levels of AAG and reduced free
fraction of basic drugs like propranolol and chlorpromazine [72]. Based on these
observations, it is possible that TB infected mice may have elevated levels of AAG which
reduces the free fraction of Lee 1810 and this ultimately results in reduction of its renal
clearance. Increase in plasma protein binding of Lee 1810 could also result in reduced
Vc /F. Reduced Vc /F of Lee 1810 in infected mice could potentially be explained by
dehydration in infected mice which resulted in reduction in average body weight from 21
g on Day 1 of treatment to 20.3 g on the final day of study leading to reduced volume of
distribution. Lee1810 based on its physico-chemical characteristics is mainly limited to
the extra-cellular space which decreases with decrease in body weight. The distribution
of Lee1810 via the diffusion process would also be reduced by the decreased fluid
content and this could also explain the reduction in Q/F observed in infected animals.
Similar observations were also seen in dehydrated goats which lost on an average 1013% of their body weight resulting in significant changes in distribution and elimination
parameters of oxytetracycline [73]. Further research needs to be conducted to better
understand the reason for the differences in pharmacokinetics between healthy and
chronically infected mice.
Effect of dosing regimen on the bacterial counts
After four weeks of therapy in mice chronically infected with 0WE, Lee 1810
exhibited a dose-dependent decrease in the bacterial counts with saturation at doses above
200 mg/kg as shown in Figure 3-10. Figure 3-11 indicates the concentration-dependent
rather than time-dependent killing characteristics of Lee 1810 as suggested for the
spectinamides similar to Lee 1810 [52]. For example, a weekly dose of 500 mg/kg when
given as 100 mg/kg QD resulted in better efficacy compared to 50 mg/kg BID. Similar
trends were also observed with dose fractionation of other weekly doses where
intermittent dosing provided improved efficacy relative to more frequent dosing
regimens. Drugs with concentration-dependent bacterial killing characteristics are
associated with a dramatic reduction in bacterial count as a consequence of a rise in drug
concentrations [74].This could potentially be explained by the ability of spectinamides to
accumulate inside the macrophages [75] promoted by lysosomal trapping and attain high
concentration to kill the intracellular form of 0WE. This intracellular accumulation would
likely be facilitated by high concentration gradients that drive drug molecules across the
bacterial cell wall into the intracellular compartment.
Model-based characterization of the natural growth of 0WE in infected mice
In the immunocompetent mouse chronic infection model, TB infection undergoes
a transition from an initial exponential growth phase to a long-term stationary phase,
where the overall growth rate diminishes markedly [76, 77]. This may be conceptualized
as a manifestation of phenotypic variants which evolved within this isogenic population
in response to the various physiological stresses like immune response, starvation,
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Figure 3-10. Bacterial burden (Log CFU) in the lungs of 0\FREDFWHULXP
WXEHUFXORVLV infected mice for the different dosing regimens evaluated in the dosefractionation study
Each column represents the amount of single dose in mg/kg. Open black circles indicate
the observed data, red points indicate the mean and blue lines indicate the standard error.
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Figure 3-11. Bacterial burden (Log CFU) in the lungs of 0\FREDFWHULXP
WXEHUFXORVLV infected mice for the different dosing regimens with same weekly dose
evaluated in the dose-fractionation study
Each column heading represents the total weekly dose amount in mg/kg. Open black
circles indicate the observed data, red points indicate the mean and blue lines indicate the
standard error.
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acidification and hypoxia [78]. The developed two-subpopulation bacterial growth model
adequately described this phenotypic switching from the fast growing metabolic state to
the slow growing/non-replicating state. Figure 3-12 for the natural bacterial growth in
the untreated group predicts that during the early phase of infection, most of the total
microbial population consists of the fast growing subpopulation (N1 ) which results in
exponential growth. Under the pressure of host immune response and other stresses, the
system gradually shifts into the stationary phase with increasing number of bacteria in the
slow growing subpopulation (N2 ), which are better equipped to sustain themselves in the
unfavorable conditions [79]. Recently, it was also demonstrated that the slow growing
subpopulation retains their metabolic activity [80], and also have the ability to reactivate
growth upon detection of a favorable signal or environment [81, 82].
The replication rate constant for the fast growing population (Krep )was found to
be 0.0327 h-1 (Table 3-5) and the corresponding doubling time was calculated as 21.2 h,
which is within the range reported in the literature (13–80 h) [19, 83-86]. This slow LQ
YLYR growth rate is a hallmark of 0WE, a characteristic that may contribute to its
persistence in the host without manifestation of clinical symptoms, yet preserving the
ability to reactivate and disseminate [87]. Since growth rate of fast growing bacteria
when described using a logistic function did not improve the fit of the natural bacterial
growth model, a simple first-order growth rate constant was used for describing
replication in the fast growing bacteria.
Model-based characterization of the dose-exposure-response relationship for Lee
1810 in 0WE infected mice
To account for the killing effect by Lee 1810 exposure, the concentration from the
central compartment of the pharmacokinetic model was linked to the natural bacterial
growth model. The drug effect was implemented as an additive component to the natural
death rate of the bacteria via an Emax -type model. (Equation 3-7). A sigmoidal Emax
model resulted in a significantly improved fit as compared to an ordinary Emax model
¨2%- - 51.3). The Hill coefficient was substantially greater than 1, which is a typical
characteristic that has also been observed for other antibiotics with concentrationdependent killing (Table 3-6) like streptomycin and rifampin, which displayed a hill
coefficient of 1.9 and 2.5 respectively. A high value of the Hill coefficient is indicative of
a steep concentration-effect relationship [74].
The concentration that produced the half-maximal effect EC50 (239 μg/mL) was
found to be much higher than MIC (1.6 μg/mL) of Lee 1810. This was expected, as EC50
describes the effect on the rate constant for drug-induced bacterial killing and is much
more realistic parameter to compare potency of compounds with regard to bacterial kill
than the MIC. The experimentally determined MIC represents the lowest concentration at
which no growth of microorganism is visible to the naked eye. MIC is usually estimated
at a fixed concentration and does not resemble the physiological conditions in which the
drug concentrations changes with time. Additionally, the inoculum size and percentage
contribution of the bacterial sub-population also contribute to the differences between
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Figure 3-12. Natural growth model fitted typical Log CFU-time profile for the
untreated group data obtained from literature and CSU studies
Model predicted Log CFU in the fast growing subpopulation (N1 , blue line), slow
growing subpopulation (N2 , green line), total population (red dash line) and observed
Log CFU (open black circles) are depicted.
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Table 3-5.
Parameter estimates of the 0\FREDFWHULXPWXEHUFXORVLV natural
growth model
Typical value
(%RSE)
-1
Krep (h )
0.0327 (33.3)
N1,0 (Log CFU) 1.93 (9)
Nmax (Log CFU) 6.44 (1.2)
0.00303 (3.6)
Kir (h-1)
RUV (% CV)
32.4 (19.6)
Parameters

%BSV
(%RSE)
70.8 (57.7)
54.7 (58.5)

Abbreviations:N1,0 , cell count of fast growing population at the initiation of the infection;
Krep , first-order replication rate constant; Nmax , maximum number of bacteria; Kir , firstorder death rate constant induced by the immune reaction; BSV, Between Subject
Variability; RUV, Residual Unexplained Variability.
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Table 3-6.

Parameter estimates of the final PK/PD model of Lee 1810
Typical value
(%RSE)
239 (0.167)
11.9 (0.485)
2.40 (0.142)
20.6 (4.2)

Parameters
EC50 (μg/mL)
Emax (h-1)
Ȗ
RUV (% CV)

Abbreviations:Emax , maximum kill rate induced by Lee1810; EC50 , concentration of Lee
1810 at half of Emax ; Ȗ, Hill function.
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EC50 and MIC [88]. MIC also assumes an all-or-nothing effect on the bacterial growth. In
contrast, EC50 captures the drug’s effect on the rate of bacterial killing. Bacterial killing
is already achieved at concentrations much lower than EC50 , but at a much lower
magnitude than at concentrations above EC50 . The effect achieved at EC50 is half of the
maximum kill rate constant achievable with Lee 1810.
The RUV in the PK/PD model was described using an additive error model. The
modeled profiles of bacterial count versus time for all the groups as well as
experimentally determined CFU counts are shown in Figure 3-13. The figure indicates
that the population predictions of the PK/PD model were in close agreement with the
observed values.
A VPC was furthermore performed to qualify the established model. The VPC
shown in the Figure 3-14 highlights the ability of the model to reasonably predict the
central tendency and the variation in the bacterial count. The impact of dosing frequency
on efficacy of Lee 1810 was also captured by the VPC where the rate of reduction in the
bacterial load with increasing doses was steeper with decrease in dosing frequency.
Alternative models and model limitations
Alternative PK/PD models could not fit the data as well. A natural bacterial
growth model with single population could describe the untreated group data equally well
as the two-subpopulation model; however it was not able to describe the dose-exposureresponse for all the different dosing regimens as a higher bacterial kill was predicted for
groups with more frequent dosing as compared to the ones with intermittent dosing. The
addition of drug effect was also tested on the slow growing population but it resulted in
over-parameterization with no convergence and poor fits.
The presented model has several limitations. Firstly, the PK/PD model was based
on the total bacterial count and no measurements were made to separately identify the
percentage of each subpopulation in the two-subpopulation modeling approach.
Quantification of each subpopulation could be helpful in distinguishing competing
models which can describe the data equally well. Secondly, the model has not been
studied for different bacterial strains, inoculum size, and immune status in different
preclinical models. For example, the initial inoculum when taken from a stationary-phase
culture will most likely have a higher proportion of slow growing bacteria as compared to
an inoculum from a log-phase culture, which could eventually have an impact on the
entire time course of relative bacterial dynamics. The mycobacterial populations in
immunodeficient strains of mice (e.g., IFN-Ȗ-knockout mice) have reduced phenotypic
heterogeneity, and higher growth potential as compared to the immunocompetent mouse
model used in this study [80]. In these situations, appropriate modification in the natural
growth model will be required to describe the bacterial kinetics. Thirdly, there are
differences in the pathophysiology and disease progression of 0WE between mice and
humans. The mouse model used in this study develops granulomas that consist of loose
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Log CFU in lung

Time (Day)

Figure 3-13. Individual Lee 1810 Log CFU-time profiles for the different treatment
groups evaluated in the dose-fractionation study
The observed Log CFU (open black circles) and population predictions (thick red line)
are depicted. The black dash line indicates the time when treatment was initiated.
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Figure 3-14. Visual predictive check (VPC) of the PK/PD model for the describing
the weekly dose-response relationship
Top Panel: Weekly dose range from 0 to 1000 mg/kg. Bottom Panel: Weekly dose range
from 0 to 5000 mg/kg. Pink, purple and green bands represent 80% prediction interval,
70% prediction interval and 60% prediction interval of simulated data respectively. The
solid black line is the median of simulated data and open circles are the observations.
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aggregates of lymphocytes and macrophages which do not progress into the well-formed
necrotic granulomas observed in humans [89]. The drug exposure in plasma may not
equilibrate homogeneously within the granulomatous lesions, and this could potentially
complicate the translation of exposure-response relationship from mice to humans.
PK/PD modeling results in perspective with antitubercular combination therapy
The developed PK/PD model was applied to simulate the relative dynamics of fast
growing and slow growing subpopulations as conceptualized in our modeling approach.
The simulations presented for different dosing regimens in Figure 3-15 suggests that
weekly doses ranging from 100 mg/kg for twice weekly dosing down to 50 mg/kg for
twice daily dosing is sufficient to kill most of the fast growing bacteria and further
increases in dose may only result in marginal increases in efficacy. Based on these
simulations, it can be speculated that further enhancement in efficacy and shortening of
treatment duration could be achieved by combining spectinamides with other antituberculosis agents which are active against the slow growing population including
pyrazinamide (PZA) and rifampin. PZA, a first line anti-tuberculosis therapy has unique
pharmacological activity as it is less effective against the fast growing tubercle bacilli but
more effective against the slow growing/non-replicating bacteria [90]. Pyrazinoic acid,
which is the active moiety of pyrazinamide, acts by disrupting the membrane energetics
and inhibiting the membrane transport function preferentially against the non-replicating
bacilli which are associated with low membrane potential and acidic pH [91]. This could
be one of the potential explanations for the significantly improved efficacy observed in a
recently conducted combination trial of Lee 1599 (structural analog of Lee1810 and a
competing lead spectinamide candidate) along with PZA in a high dose aerosol mice
infection model that was performed by Dr. Anne Lenaert’s research group at Colorado
State University (Figure 3-16). Lee 1599 was found to be as efficacious as Lee 1810,
whereas PZA had modest activity as a single agent. The combination of Lee 1599 and
PZA resulted in a significant reduction in bacterial count compared to the same drugs
when used alone. This synergistic effect in combination could possibly be the outcome of
each drug’s ability to act on a different subpopulation of bacteria.
Looking ahead, this PK/PD model could also be used for simulating untested
scenarios and for quantitative comparison of different dosing strategies as well as
competing lead candidates. Furthermore, the PK/PD relationship established with this
model could be integrated with the information about antibiotic susceptibility, drug
associated adverse effects, and pharmacokinetics in different patient populations to
perform simulations for identifying clinically optimum dosing regimens and also help in
informing clinical trial designs. This semi-mechanistic model-based approach also
provides a framework for evaluating the dose-exposure-response analysis of other
investigational anti-tuberculosis agents. The differentiation of drug-specific and
mycobacterium specific parameters makes it convenient to apply this model for scenarios
other than those reported for this drug and study.
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Figure 3-15. PK/PD model predicted Log CFU in the fast growing state, slow
growing state and total population for the different treatment groups evaluated in
the dose-fractionation study
Model predicted Log CFU in the fast growing subpopulation (N1, blue line), slow
growing subpopulation (N2, green line) and total population (red dash line) are depicted.
The black dash line indicates the time when treatment was initiated.
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Fast growing
Slow growing

Figure 3-16. ,QYLYR efficacy trial showing bacterial burden in the lungs for combination of spectinamides with pyrazinamide
in a BALB/c mouse (n=3-6) infection model following high dose aerosol infection of 0\FREDFWHULXPWXEHUFXORVLV Erdman (mean
± s.e.m.)
Lee 1599 /Lee 1810 were subcutaneously dosed at 200 mg/kg and pyrazinamide (PZA) was orally dosed at 150 mg/kg. All treatments
were given QD, 5 days a week for 4 weeks.
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In summary, the efficacy of Lee 1810 was largely driven by concentrationdependent killing, and this supports the use of intermittent dosing. A two-subpopulation
bacterial growth model adequately described the phenotypic heterogeneity associated
with 0WE infection in immunocompetent mice. This model component was integrated
with the pharmacokinetics of Lee 1810 to successfully describe its dose-exposureresponse relationship. The semi-mechanistic PK/PD modelling approach allowed for a
more comprehensive characterization of drug efficacy as compared to the MIC based
PK/PD index approach. Based on the PK/PD model it was hypothesized that improved
efficacy could be achieved by combining spectinamides with sterilizing anti-tuberculosis
agents. This hypothesis was supported by the synergistic activity obtained with
combination of Lee 1599 and PZA. Preclinical PK/PD assessments of Lee1810 will be
useful for determining it’s preclinically and clinically optimum dosing regimen. This
semi-mechanistic model-based approach also provides a framework for investigating the
PK/PD relationship of other investigational anti-tuberculosis agents.
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CHAPTER 4. COMPARATIVE PHARMACOKINETICS OF SPECTINAMIDE
ANTIBIOTIC LEE 1599 AFTER INTRATRACHEAL AND SUBCUTANEOUS
ADMINISTRATION FOR THE TREATMENT OF TUBERCULOSIS
Introduction
Spectinamides are a novel semisynthetic series of spectinomycin analogs with
excellent narrow-spectrum antitubercular activity. They exhibit selective ribosomal
inhibition and are not cross-resistant with the existing tuberculosis therapeutics.
Spectinamides maintain activity against Multidrug-resistant (MDR) and extensively drugresistant (XDR) tuberculosis. Physico-chemically, spectinamides are hydrophilic in
nature making them highly water soluble and exhibit low plasma protein binding.
However, these analogs have poor permeability across the intestinal barrier, limiting their
bioavailability and thus oral use. Consequently, a parenteral route such as subcutaneous
(SC) injection was selected for dosing in efficacy studies. The lead spectinamide Lee
1599 upon SC administration in a mouse model of 0\FREDFWHULXPWXEHUFXORVLV (0WE)
infection at a dose of 200 mg/kg QD (5 days a week) for 28 days resulted in 1.57 Log
CFU (colony forming unit) reduction in the lungs. This excellent anti-mycobacterial
activity of Lee 1599 was similar to streptomycin at similar doses in the lungs [52].
Historically, orally and parenterally administered antibiotics have been used to
treat patients with lung infections, but the downside is that they do not directly target the
lungs [92]. Therefore in order to deliver even moderate concentrations of antibiotic to the
lungs, the primary site of infection, the required overall systemic exposure is usually high
and thus increases the potential for the emergence of side effects [93, 94]. The delivery of
antibiotics via the inhalation route potentially leads to much higher concentrations of
antibiotic in the lungs. It also increases the possibility of targeting alveolar macrophages
which may allow the delivery of drugs to the intracellular (phagosomal) compartment.
Additionally, inhaled therapies have the potential to stimulate innate bactericidal
UHVSRQVHVDQGRUDQWLJHQSUHVHQWLQJIXQFWLRQVPRUHHI¿FLHQWO\[95]. The development of
resistance during antimicrobial therapy stems at least partially from the fact that when
administered systemically many antimicrobial drugs fail to reach therapeutically effective
concentrations in the lungs or penetrate into the alveolar macrophages, a reservoir for
intracellular infections [96, 97]. High local concentrations are consequently needed to
prevent amplification of less sensitive pathogens, especially when located intracellularly
[98]. Intrapulmonary administration can deliver high concentrations of drug to the lung
tissue and macrophage cytosol, poWHQWLDOO\VXI¿FLHQWWRSUHYHQWRURYHUFRPHGUXJ
resistance [97, 98].
Inhalational delivery has revolutionized the treatment of chronic 3VHXGRPRQDV
DHUXJLQRVD infections in cystic fibrosis (CF) since the FDA approval of TOBI
(tobramycin inhalation solution) in 1997 followed by CAYSTON (aztreonam for
inhalation solution) in 2010. In Europe, a third antibiotic from the polymyxin family is
approved in CF, colistimethate sodium, a prodrug of colistin, but it is not approved in the
United States [94]. Use of inhaled antibiotics in CF has been shown to decrease
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3VHXGRPRQDVDHUXJLQRVD colonization, delay onset of chronic infection, increase lung
function, improve the quality of life, and correlates with a reduction in morbidity, the
number of exacerbations and the number of hospital admissions when compared to
systemic administration [94].
Based on the experiences described above, the efficacy of Lee 1599 had been
evaluated after intratracheal (IT) administration in the same mouse model of 0WE
infection as used in our previous studies [99]. A dose of 200 mg/kg TIW (3 days a week;
Monday, Wednesdays and Fridays) for 28 days demonstrated excellent efficacy with a
2.2 Log CFU reduction in the lungs. This antitubercular activity was comparable to that
of rifampin (administered orally at 10 mg/kg, 5 days per week) [52].
It was hypothesized that the excellent efficacy following intrapulmonary delivery
of Lee 1599 may be a result of extensive distribution of the free drug within the lungs. In
this chapter, we test this hypothesis by performing a comparative tissue distribution study
of Lee 1599 in BALB/c mice following SC and IT administration. In addition to the
lungs, distribution in other organs such as spleen, liver and kidneys were also evaluated
to better understand the impact of tissue distribution on overall efficacy of Lee 1599.
Material and Methods
Animal study
Healthy female BALB/c mice (n= 15) were administered a dose of 200 mg/kg of
Lee 1599.2HCl by IT aerosol delivery with a PennCentury MicroSprayer PennCentury
Inc. (Wyndmoor, PA) as previously described [99]. The tip of the device was inserted up
WRWKH¿UVWEURQFKLDOELIXUFDWLRQRIWKHWUDFKHDRIWKHDQHVWKHWL]HGDQLPDOE\SDVVLQJWKH
nose and throat and making it easier to precisely control the delivered dose. This is in
contrast to metered-dose inhalers and dry powder inhalers and/or nebulizers in animal
VWXGLHVZKLFK¿OWHUWKHDHURVROWKURXJKWKHQDVRSKDU\Q[DUHSURQHWREHWZHHQ-subject
variability and are not capable of targeting a desired, predetermined area of the lungs. At
pre-dose and 0.25, 1, 3, and 8 h after administration, mice (n=3) were sacrificed
humanely. Lungs, spleen, liver, and kidneys were immediately harvested and frozen in
liquid nitrogen. Blood obtained by cardiac puncture was collected in heparinized
collection tubes, and plasma was separated immediately by centrifugation (10,000 g for
10 min at 4°C). All the plasma and tissue samples were stored at -70°C until analysis.
For comparison of plasma pharmacokinetics of Lee 1599, healthy BALB/c female
mice (n=15) were dosed via the SC route at 200 mg/kg of Lee 1599.2HCl. Blood and
tissue samples were collected and processed as described for IT administration.
All animal experiments were conducted in accordance with the Animal Welfare
Act and the Public Health Service Policy on Humane Care and Use of Laboratory
Animals. The study protocols were approved by the Institutional Animal Care and Use
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Committees of Colorado State University and the University of Tennessee Health
Science Center, respectively.
Bioanalysis
Concentrations of Lee 1599 in plasma and tissues were determined by a validated
liquid chromatography tandem mass spectrometry assay. The frozen tissues were thawed
at room temperature and weighed. For every 1 g of tissue 4 mL of water was added for
homogenization using an Ultra Turrax homogenizer (IKA, Wilmington, NC). To prevent
cross contamination between two samples, the plunger of the homogenizer was washed
with methanol and water after each sample. Samples were further prepared by protein
precipitatioQZLWKPHWKDQRO VSLNHGZLWKWKHLQWHUQDOVWDQGDUGƍ-dihydro-ƍ-deoxy-ƍ 5 isopropylacetylamino spectinomycin) followed by centrifugation at 10,000 g for 10 min
DW&&KURPDWRJUDSKLFVHSDUDWLRQRIWKHVXSHUQDWDQWZDVFDUULHGRXWRQD/XQDȝP
hydrophobic interaction liquid chromatography (HILIC) 100 × 4.6 mm column
(Phenomenex, Torrance, CA) using a gradient mobile phase of methanol and 10 mM
ammonium formate, pH 2.75, at a flow rate of 0.4 mL/min. Detection was performed
with an API 4500 triple-quadruple mass spectrometer (ABI-Sciex, Foster City, CA) with
electrospray ionization in multiple reaction monitoring mode using the mass transfers of
m/z 487.2/207.1 for Lee 1599 and m/z 418.3/207.1 for the internal standard (Lee 1369).
Calibration curves were constructed for each test compound and validated with spiked
samples of mouse plasma or respective homogenized tissue.
Pharmacokinetic analysis
Pharmacokinetic profiles of Lee 1599 were analyzed by standard noncompartmental procedures using Phoenix WinNonlin 6.3 (Pharsight Corporation,
Mountain View, CA) in plasma and tissues. Penetration of drug in tissues was estimated
from the ratios of the area under the concentration-time curve from time 0 to infinity
(AUC0–) for tissues compared to the AUC0–in plasma. Total plasma clearance was
calculated as ratio of dose and resulting plasma AUC0–.
Results and Discussion
After IT and SC administration Lee 1599 demonstrated very rapid absorption into
plasma (Figure 4-1). The maximum plasma concentration Cmax was two times higher
after IT than SC administration (Table 4-1 and Table 4-2). This is in line with the fact
that the lungs are well known to be naturally permeable to small molecule drugs [100].
Although the mechanism of absorption of molecules after pulmonary deposition is still
being researched, it seems that the lung’s tremendous surface area, very low surface fluid
volume, thin diffusion layer and paracellular transport are some of the factors which
contribute towards the rapid absorption of Lee 1599 into the systemic circulation. For
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Subcutaneous

Intratracheal

Figure 4-1. Measured concentration-time profiles (mean ± s.e.m) in different
tissues/plasma relative to the minimum inhibitory concentration (MIC) after
intratracheal (IT) (Left Panel) and subcutaneous (SC) administration (Right Panel)
of Lee 1599 in mice at a dose of 200 mg/kg (n=3 at each time point)
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Table 4-1.
Penetration ratios after intratracheal (IT) administration of Lee 1599
in mice at a dose of 200 mg/kg
Sample *AUC0-8h ^Cmax
Plasma
Lung
Spleen
Liver
Kidney

284
695
9.36
65
95.9

406
805
12.9
63.4
117

#

Penetration
ratio
1
2.45
0.0330
0.229
0.338

Abbreviations: AUC0-8h: Area under the curve from time zero to 8 h; Cmax, Peak
concentration.
*AUC units for plasma (h.ȝJP/ DQGIRUWLVVXHV KȝJJ
^ Cmax units for pODVPD ȝJP/ DQGIRUWLVVXHV ȝJJ
ܥܷܣ௦
# ܲ݁݊= ݅ݐܽݎ ݊݅ݐܽݎݐ
ܥܷܣ௦
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Table 4-2.
Penetration ratios after subcutaneous (SC) administration of Lee 1599
in mice at a dose of 200 mg/kg
Sample
Plasma
Lung
Spleen
Liver
Kidney

*

AUC0-8h

^

Cmax

149
21.8
17
84.1
191

192
9.31
4.31
15.2
38.7

#

Penetration
ratio
1
0.146
0.114
0.564
1.28

Abbreviations; AUC0-8h: Area under the curve from time zero to 8 h; Cmax, Peak
concentration.
*AUC units for plasma (h.ȝJP/ DQGIRUWLVVXHV KȝJJ
^ Cmax XQLWVIRUSODVPD ȝJP/ DQGIRUWLVVXHV ȝJJ
ܥܷܣ௦
# ܲ݁݊= ݅ݐܽݎ ݊݅ݐܽݎݐ
ܥܷܣ௦
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small molecule drugs which are not dissolution rate-limited, including Lee 1599, the
intrinsic absorption rates across the lungs are usually fast with absorption half-OLYHVRI
h, and are independent of lipophilicity or involvement of transporters [101]. The
absorption rate also varies within the respiratory track between the epithelial cells and
alveolar cells. There is experimental evidence that absorption of small molecules through
the peripheral region is twice as fast compared to the central region of the lungs [102]. In
this pilot study for Lee 1599, the disposition pattern of the formulation in the lungs was
not evaluated. However, the rapid pulmonary absorption rate of Lee 1599 suggests that
the drug is being delivered to the peripheral region of the lungs. This is desirable as 0WE
usually resides in the deeper regions of the lungs [103].
The systemic relative bioavailability after IT versus SC administration was
1.91(Table 4-3). This suggests that the drug is permeable across the lung barrier to a
larger extent compared to absorption from the SC route. The high systemic plasma
exposure of Lee 1599 after IT administration (Figure 4-2) also suggests that close to the
total inhaled dose was actually deposited in the lungs and that there was negligible firstpass metabolism. Most of the small molecule drugs currently used for inhalation,
including bronchodilators and tobramycin, are not dissolution rate-limited, and have
approximately 100% bioavailability for the fraction of the dose deposited in the lungs
irrespective of their permeability characteristics [101]. The relatively lower
bioavailability after SC administration has also been observed with other aminocyclitol
antibiotics like trospectinomycin which was 75% bioavailable in rats following SC
administration [104]. This could potentially be explained by the incomplete and slow
absorption from the subcutaneous site of administration. Similar to IV administration, the
high clearance of Lee 1599 predominantly through renal excretion limits the systemic
exposure to a relatively short duration [52].
Information about tissue distribution is very important for the evaluation of
efficacy and potential toxicity. As expected, the highest exposure of Lee 1599 after IT
administration was attained in the lungs which was 2.5 times higher than plasma (Figure
4-2 and Table 4-1). This is highly desirable as the lungs are the main site of infection in
pulmonary TB. Dibasic compounds such as Lee 1599 usually have longer lung retention
as compared to neutral and cationic compounds, which may be explained by the
phenomenon of ‘lysosomal trapping’ where the basic drug accumulates in the acidic
environment of lysosomes, which acts as a reservoir [105]. Additionally, spectinamides
also have the ability to penetrate inside the macrophage, which is one of the main sites
for intracellular survival and replication of 0WE [75]. Macrophage uptake of spectinamide
Lee 1329 was found to be significantly higher than spectinomycin, the parent compound
of Lee 1329, and streptomycin, a second line anti-tuberculosis agent [75].
Inhalation delivery allows easier accessibility of Lee 1599 to alveolar
macrophages, which are the predominant form of infected cells in TB, thereby creating
high localized concentrations of the drug that can kill the intracellular 0WE [89]. The
circulation of alveolar macrophages also promotes drug distribution into the poorlyventilated areas of the lungs which are often a safe-haven for 0WE [106]. Experimental
evidence from rat studies involving IT administration of soluble compounds indicates
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Table 4-3.
Pharmacokinetic parameters for plasma concentration-time profiles
after subcutaneous (SC) and intratracheal (IT) administration of Lee 1599 in mice
at a dose of 200 mg/kg
Route
IT
SC

Dose
AUC0-8h
(mg/kg) (h.ȝJP/
200
284
200
149

CL/F
t1/2
F
(L/h/kg)
(h) (Relative to SC)
0.704
0.785
1.91
1.38
0.847
1

Abbreviations; AUC0-8h: Area under the curve from time zero to 8 h; CL/F, Total body
clearance corrected for bioavailability, t ½, Half-life; F, Bioavailability.
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Figure 4-2. Measured concentration-time profiles (mean ± s.e.m) in different
tissues relative to the minimum inhibitory concentration (MIC) after intratracheal
(IT) and subcutaneous (SC) administration at a dose of 200 mg/kg of Lee 1599 in
mice (n=3 at each time point)
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that t1/2 observed in lungs often mimics the apparent t1/2 observed in plasma [100]. This is
consistent with the observations in our study.
Although Lee 1599 is getting rapidly cleared from the lungs and plasma, excellent
efficacy was still observed by thrice a week IT administration in mice. The potential
explanation could be its concentration-dependent killing pattern and lengthy postantibiotic effect (PAE) of 133 h at 10×MIC [52]. The concentration of a drug is one of
the major determinants of PAE. For example, the PAE of penicillin G gradually increases
with increase in its concentration [107, 108]. In case of Lee 1599, higher concentrations
achieved in the plasma and lungs after IT administration could potentially be associated
with longer PAE as compared to SC administration.
Following IT administration, Lee 1599 distributes to a similar extent in the
kidneys and liver with penetration ratios of 0.338 and 0.229 respectively (Figure 4-2),
although the Cmax in the liver was approximately half that in the kidneys. Passive
diffusion across the cell membrane is highly unlikely for Lee 1599 as it is very polar
(cLog P = -2.5) and based on its pKa of 8 and 10, it is expected to be largely in ionized
form at physiological pH. This strongly suggests an active role of transporters involved in
the uptake into kidneys and liver. The Biopharmaceutics Drug Disposition Classification
System (BDDCS) classifies compounds into four types based on the solubility and
permeability and is useful for predicting the role of transporters in the disposition of
novel entities during the early stages of drug discovery. As Lee 1599 exhibits high
solubility and poor permeability, it can be categorized as BDDCS Class 3 compound.
BDDCS predicts that for class 3 drugs uptake transporters will be important for its entry
into the liver [109]. The endocytic receptor complex formed by megalin and cubulin is
known to transport aminoglycosides into the renal tubular epithelial cells [110]. Megalin
associated uptake transport has also been associated with accumulation of colistin in the
kidneys [111]. Similar to the kidneys, accumulation in the liver may also be assisted by
hepatic uptake transporters. The highest tissue levels of trospectinomycin were found in
the liver [112]. The mechanism behind selective hepatic sequestration was not clear;
however it is likely that hepatic uptake transporter may be associated with it.
The lowest penetration ratio was observed in the spleen with both SC and IT
administration indicating that Lee 1599 may not be successful in treating TB infections
that have disseminated into the spleen (Figure 4-2). This was supported by the relatively
lower reduction in bacterial load in the spleen as compared to the lungs observed after IT
and SC administration of Lee 1599 [52]. This limitation, however, can likely be
addressed by using Lee 1599 in combination therapy with other antitubercular agents
which have better penetration and efficacy in the spleen.
In the present study, tissue penetration was found to be higher in the kidneys and
liver, whereas it was lower in the lungs and spleens. In a previously conducted mass
balance study of Lee1329, a structurally similar spectinamides analogue, in rats after IV
administration [75], similar drug distribution pattern was observed with highest tissue
penetration in the kidneys followed by liver while lower and similar penetration in lungs
and spleen.
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Conclusions
IT administration of Lee 1599 provides higher exposure in the lungs compared to
the SC route. As the lungs are the main site of infection, this could potentially explain the
improvement in efficacy with a lower weekly dose followed by IT administration. In
spite of being highly hydrophilic, Lee 1599 accumulates in kidney and liver suggesting a
potential role of uptake transporters in these organs. Spleen had the lowest exposure
among all the tissues investigated following IT and SC administration. Overall, these
results are encouraging to further pursue pulmonary delivery as an administration route
for spectinamides in the treatment of tuberculosis.
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CHAPTER 5. PHYSIOLOGICAL MODEL-BASED PREDICTION OF THE
HUMAN PHARMACOKINETICS OF LEE 1599, A NOVEL ANTITUBERCULOSIS AGENT
Introduction
The translation from the preclinical stage to the clinic is one of the most critical
steps in drug development with an average attrition rate of 30% [113]. Successful human
pharmacokinetic prediction based on preclinical data can be highly beneficial for any
drug development program for calculating the first-in-human dose. One of the most
common approaches used for prediction of human pharmacokinetics is allometric scaling,
which typically uses body size based on a power law function to extrapolate clearance
and volume of distribution from preclinical species to humans [114]. Allometric scaling
adjusted for maximum lifespan potential and brain weight have also been suggested in
order to improve its predictive capability [115].
Physiologically based pharmacokinetic (PBPK) modeling is an alternative
approach which combines species-specific physiological features along with drugspecific LQVLOLFR/LQYLWUR input parameters for prediction of pharmacokinetics in a species
[28, 116]. Its mechanistic and more realistic modeling approach compared to empirical
compartmental models has led to its wide spread use for studying the disposition of
xenobiotics. Because of their intricacy, PBPK models are able to achieve a detailed
quantitative assessment of the plasma and tissue disposition of drugs along with ease of
scaling up the model to different species since the structural model is relatively common
to most mammalian species and only needs size and blood flow related species-specific
adjustments [117]. This approach in combination with physiological scaling factors has
been successfully used for cross-species extrapolation of drugs like cyclosporine and
docetaxel [118, 119], and in combination with pharmacodynamic data, it can also help to
guide optimized clinical dosing. These models can also be used for predicting the
pharmacokinetics of drugs in complex scenarios which arise as a result of multivariate
changes to intrinsic (e.g., disease states, age, pharmacogenomics) and extrinsic (e.g.,
drug-drug interaction) factors.
Lee 1599 has emerged as one of the potential lead spectinamide candidates based
upon its excellent microbiological, safety and efficacy profile for treatment of
tuberculosis. It binds to a site within the mycobacterial 30S ribosome and inhibits its
protein synthesis with a minimum inhibitory concentration (MIC) of 0.8 ȝJP/ [53]. It
evades the efflux pump Rv1258c upregulated in drug resistant bacteria, thereby gaining
significant efficacy in both LQYLWUR and LQYLYR models of tuberculosis infection. Unlike
aminoglycosides, Lee 1599 does not inhibit human mitochondrial translation which is
linked to ototoxicity. In this present study, we present an application of PBPK modelling
and simulation to predict human pharmacokinetics of Lee 1599 which was conducted in
the following steps:
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1.

Develop and optimize a PBPK model that can describe the pharmacokinetics of
Lee 1599 in rats after intravenous (IV) administration,

2.

Prospectively qualify the performance of the model by predicting the
pharmacokinetics of Lee 1599 in mouse after subcutaneous (SC) administration,
and

3.

Extrapolate the PBPK model to predict pharmacokinetics of Lee 1599 in human
after IV administration.
Materials and Methods

Chemicals and reagents
Spectinamide antibiotic Lee 1599 (3’-Dihydro-3’-deoxy-3’(R)- (5-chloropyridin2-yl)acetylamino spectinomycin), as shown in Figure 5-1 was synthesized in Dr. Richard
E. Lee’s Lab at St. Jude Children’s Research Hospital, Memphis, TN. Acetonitrile,
methanol, HPLC grade water, formic acid and nonafluoropentanoic acid were purchased
from Fisher Scientific (Pittsburgh, PA). Drug free BALB/c mouse plasma and rat plasma
was purchased from Innovative Research (Novi, MI).
Protein binding
The plasma protein binding of Lee 1599 in different species was determined using
equilibrium dialysis method with ready-to-use RED device inserts (Thermo Scientific,
Rockford, IL) in base plates containing plasma and a buffer chamber for analysis. Two
concentrations (0.5 and 5 mg/L) of Lee 1599 were prepared in rat and mouse plasma. 200
ȝ/RIWKHSODVPDVDPSOHZDVDGGHGWRWKHFHQWUDOFKDPEHUDQGȝ/RIEODQNLVRWRQLF
phosphate buffer, pH 7.4 to the peripheral chamber of dialysis base plate. The base plate
was sealed and then incubated at 37oC at 100 rpm on an orbital shaker for 4 h to achieve
equilibrium. At the end of incubation, the drug concentration was determined in plasma
and buffer using an LC-MS/MS assay. The free fraction of the drug was calculated as
ratio of the concentrations in the buffer and in plasma. The results are expressed in terms
of fraction of drug unbound to plasma proteins (fu).
Microsomal incubations
,QYLWUR microsomal metabolic stability of the Lee 1599 was performed in pooled
UDWOLYHUPLFURVRPDOSUHSDUDWLRQV %'%LRVFLHQFHV:REXUQ0$ ȝ0 stock solution
of Lee 1599 and 10 mg/mL of microsomal protein solution were prepared in phosphate
EXIIHUVROXWLRQ S+ 7KHILQDOUHDFWLRQPL[WXUH ȝO FRQVLVWHGRIȝ/RI
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Figure 5-1.

Structure of Lee 1599
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PLFURVRPDOSURWHLQVROXWLRQ PJP/ ȝ/RI1$'3+UHJHQHUDWLQJVROXWLRQ
containing 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2 and 1 unit/mL
glucose-6-phosphate dehydrogenase (BD Biosciences, Woburn, MA). Reaction was
starteGE\DGGLWLRQRIȝ/RI/HHVROXWLRQ ȝ0 WRWKHUHDFWLRQPL[WXUHDQG
incubated at 37°C for 90 minutes. Then the sample was collected and immediately
quenched by the addition of ice-cold methanol containing an internal standard to stop the
reaction. The quenched samples were centrifuged and the supernatant was analyzed by
LC-MS/MS assay to measure the parent compound (Lee 1599) remaining after 90 min of
incubation period. Verapamil with known significant phase I metabolism was used as
positive control while deactivated microsomes was used as negative control.
Formulation preparation and administration
A dosing solution of Lee 1599.2HCl (10 mg/kg) was freshly formulated in water
(50%) and Plasmalyte A (50%). The IV dose was administered via a femoral vein
catheter followed by flushing the catheter with saline followed by heparinized glycerol
locking solution to clear the dead space in the catheter. For subcutaneous administration,
dosing solution of Lee 1599.2HCl was freshly formulated in water (33.8 %) and
Plasmalyte A (66.3%) and was administered subcutaneously using a 29 gauge insulin
syringe.
Pharmacokinetic studies in rats and mice
The LQYLYR pharmacokinetic studies presented were performed at the University
of Tennessee Health Science Center protocol numbers 13-165 and 15-121, approved by
the Institutional Animal Care and Use Committee of the University of Tennessee Health
Science Center. Animal studies were conducted according to the guideline of Animal
Welfare Act and the Public Health Service Policy on Humane Care and Use of
Laboratory Animals. The animals were kept on a 12 h light/ dark cycle with access to
food and water DGOLELWXP.
Lee 1599 was administered to groups of catheterized (jugular and femoral veins)
female Sprague-Dawley rats (8–10 weeks old, 200–225 g, n = 6, Harlan BioScience,
Indianapolis, IN) intravenously at a dose of 10 mg/kg body weight. Thirteen serial blood
VDPSOHV aȝ/ ZHUHFROOHFWHGLQ%'0LFURWDLQHUSODVPDVHSDUDWRUWXEHVFRQWDLQLQJ
lithium-heparin via the jugular vein catheter at 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10,
24 and 48 h after dosing. Plasma was separated immediately by centrifugation (10,000g
for 10 min at 4°C) while cumulative urine samples were collected for 48 h.
Healthy female BALB/c mice (6–8 weeks old, ~20 g) weighing approximately
20-25 g were obtained from Harlan Bioscience (Indianapolis, IN). Lee 1599 was
administered to a group of 15 mice by subcutaneous injection at a dose of 200 mg/kg.
Blood samples were in BD Microtainer plasma separator tubes containing lithiumheparin collected at 0.083, 0.25, 0.5, 1, 2, 3, 5, 8, 12 and 24 h after administration. Each
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mouse provided two blood samples, one by a one-time retro-orbital bleed under
isoflurane anesthesia, and the other by cardiac puncture under isoflurane anesthesia
followed by euthanasia through cervical dislocation. Plasma was separated immediately
E\FHQWULIXJDWLRQDVGHVFULEHGDERYHDQGVWRUHGDWí&XQWLO/&-MS/MS analysis.
Bioanalysis
Plasma and urine samples were prepared by protein precipitation with methanol
VSLNHGZLWKWKHLQWHUQDOVWDQGDUGƍ-dihydro-ƍ-deoxy-ƍ 5 -isopropylacetylamino
spectinomycin) followed by vortexing for 1 min, and then centrifugation at 10,000g for
10 min at 4°C. The supernatant was seSDUDWHGDQGȝ/RIVXSHUQDWDQWZDVDQDO\]HG
using high-performance liquid chromatography coupled with tandem mass spectrometry
(LC-MS/MS). Chromatographic separations were carried out using a Shimadzu Nexera
XR (LC-20ADXR) liquid chromatograph (Shimadzu Corporation, Kyoto, Japan)
consisting of two pumps, online degasser, system controller and an autosampler. Liquid
FKURPDWRJUDSK\ZDVSHUIRUPHGRQ:DWHUV6\PPHWU\ȝP&îPPFROXPQ
(Waters, Milford, MA). The mobile phase was solvent A (water with 1.6%
nonafluoropentanoic acid and 0.7 % formic acid) and solvent B (90% acetonitrile with
0.8% nonafluoropentanoic acid and 0.35% formic acid) in the gradient mode as follows:
0–0.5 min, 20% B; 0.5–1.6 min, 20–90% B; 1.6–2 min, 90% B; 2-2.5 min, 90-20% B,
2.5–3 min, 20% B at a flow rate of 0.5 mL/min. Analytes were detected with a API 5500
triple-quadruple mass spectrometer (Applied Biosystems, Foster City, CA) with
electrospray ionization in multiple reaction monitoring mode using the compoundspecific mass transfers of m/z of 487.2/ 207.1 for Lee 1599 and m/z of 418.3/207.1 for
Lee 1369.
Two calibration curves ranging from 1.95 to 2,000 ng/mL and 1.95 to 1000
μg/mL were constructed and validated with spiked samples of rat and mouse plasma.
Samples with concentrations above 2000 ng/mL were analyzed with the higher
calibration range. The peak area ratios of analyte to internal standard was linear over the
concentration range tested for both compounds, with correlation coefficients (weighted
least-square linear regression analyses) >0.997. Accuracy (deviation of the analyzed
quality control samples from nominal values) was within ±3% over the entire range of the
calibration curve, and precision (coefficient of variation of repeated measurements of the
quality control samples) was <2%.
Pharmacokinetic data analysis
Naïve data pooling was performed with the mean values of plasma concentrations
in plasma at each time point plotted against time to generate concentration-time profile.
The pharmacokinetic parameters were estimated using Phoenix WinNonlin 6.3 (Pharsight
Corporation, Mountain View, CA) by noncompartmental analysis.
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Overall strategy for development of the PBPK model for cross-species extrapolation
As a first step, a PBPK model was developed for describing the pharmacokinetics
of Lee 1599 in rats after IV administration. An independent parameter (cLogP) was
manually adjusted to optimize the PBPK model with respect to the IV pharmacokinetics
in rats. Before subsequently predicting the pharmacokinetics in humans, a cross-species
extrapolation was performed by predicting the pharmacokinetics in mice after SC
administration. Once the optimization of the systemic distribution and clearance of Lee
1599 had been completed using the rat IV plasma pharmacokinetics as described above, a
first-order absorption was estimated for SC administration by fitting the model to the
experimental data obtained from the SC pharmacokinetic study in mice, thereby leaving
all other drug-specific parameters unchanged and switching the system specific
parameters from the rat to the mouse species. After evaluating its predictive performance
in mice, the model was finally used to predict human pharmacokinetics with input for
human clearance which was scaled from rat clearance. A virtual human population of 100
individuals was simulated from distributions of anatomical, demographic, and
physiological variables derived from real patient populations using a Monte Carlo
simulation approach to account for the variability observed in clinical populations [120].
PBPK model structure
The PBPK modeling and simulation was performed using the PK-Sim software
platform (Version 6.1, Bayer Technology Services GmbH, Leverkusen, Germany) [121].
The generic PBPK model structure consists of a series of compartments corresponding to
different tissues which are connected by the circulation system with a mass balance for
each compartment [122].
PBPK model parameterizations are broadly categorized into system-specific and
drug-specific parameters. System-specific physiological parameters such as organ
volumes, blood flow rates or tissue composition are provided in the software, and were
originally collected from large numbers of literature sources [123].
The second set of parameters required for PBPK models are drug-specific, which
includes physiochemical data (cLogP, MW and pKa) listed in Table 5-1 and ADME
properties. cLogP for Lee1599 was estimated using the ChemDraw Ultra software
(version 11.0, Cambridge Software Company), while the pKa was estimated using
MarvinSketch 5.10.4 (ChemAxon Lt., Budapest, Hungary). Partition coefficients (Kp) are
also an important set of compound-specific parameters which determine the distribution
of the drug into different compartments. The Kp value for each tissue is defined as the
ratio of total drug exposure in the tissue to the total drug exposure in the plasma at steady
state. In the past, Kp values had to be determined experimentally by performing extensive
tissue distribution studies. However, recent development of algorithms based on
physicochemical and LQYLWUR binding characteristics, including molecular weight,
lipophilicity and protein binding of the drug, allows prediction of Kp values with
reasonable degree of accuracy. The PK-Sim software offers several generic algorithms

69

Table 5-1.

Physicochemical characteristics of Lee 1599
Physicochemical parameter
cLog P
Molecular Weight (MW)
pKa

70

Estimate
-2.5
486.9
8,10

for calculation of partition coefficients, and amongst those the distribution model by
Schmitt was selected for this project.
Knowledge about the ADME characteristics of the compound is also vital for
successful prediction by the model. Clearance is one of the key parameters required for
PBPK model predictions. For drugs which are predominantly cleared by the liver, the LQ
YLYR clearance is usually extrapolated from LQYLWUR systems including microsomes and
hepatocytes using physiological scaling factors. However, for the drugs which are renally
cleared, the LQYLYR clearance is used as input or it is predicted using allometric scaling
[116]. Spectinamide antibiotic Lee 1599 is metabolically stable and is nearly exclusively
cleared by the kidneys via glomerular filtration and active secretion processes. For
describing the pharmacokinetics of Lee 1599 in rat and mouse, the LQYLYR clearance was
used as an input in the PBPK model. In the absence of human pharmacokinetic data, the
clearance in humans had to be determined by scaling from preclinical species. As renal
clearance with net active secretion is the main route of elimination for Lee 1599, it
requires using scaling approaches which are specifically applicable for drugs which are
predominantly actively secreted in urine. Paine HWDO [124] proposed three different
approaches for prediction of human renal clearance from preclinical species for drugs that
exhibit active secretion or net reabsorption. These three approaches are as follows:
Direct correlation method: The renal clearance value in humans is estimated
from the clearance in rats using the following equation:
ܮܥ,௨ = ܮܥ, ௧ × ൬

ೠ,ೠೌ
ೠ,ೌ

൰×ቀ

ிೠೌ
ிೌ

ቁ

Eq. 5-1

where CLr,human and CLr, rat are the renal clearances in human and rat, fu,human and fu,rat
are the unbound fractions in plasma, and KBFhuman (1.3 L/min) [125] and KBFrat (0.0104
L/min[126] are the respective kidney blood flows. fu has been found to consistent across
rat, mouse and human for most of the other analogs of spectinamide series [127]. As
fu,human was not yet available for Lee 1599, it was assumed to be similar to the fu
determined experimentally for Lee 1599 in rat and mouse plasma.
Simple allometry: The unbound clearance is scaled across preclinical species
using the following relationship:
ܮܥ = )ܹܤ( × ݔ௬

Eq. 5-2

where CLr is renal clearance, BW is body weight, and x and y are the coefficient and
exponent of the allometric equation, respectively. Using this established relationship, the
human clearance is predicted.
Mahmood’s renal clearance scaling method: The simple allometry method was
modified by introducing a species scaling factor (SSF) which takes into account the
physiological differences in kidney between human and preclinical species.
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where GFR is the glomerular filtration, KBF is the kidney blood flow, and KW is kidney
weight.
The first method is single species scaling approach, whereas the latter two
approaches require IV clearance in at least two preclinical species for extrapolation of
human clearance. For Lee 1599, IV clearance was only available in rats and therefore, the
direct correlation method was used for scaling of human clearance.
Results and Discussion
Pharmacokinetics of Lee 1599 in rats and mice
The concentration-time profile of Lee 1599 displayed bi-exponential decline upon
IV administration (10 mg/kg) in rats and SC administration (200 mg/kg) in mice. In
agreement with the theory of allometry, the weight normalized clearance in rats was
slightly lower than in mice, whereas weight normalized volume of distribution was
similar in both species (Table 5-2 and Table 5-3). The protein binding was also
comparable in both species with most of the drug available in unbound form (Table 5-2
& Table 5-3). The fraction of drug eliminated in unchanged form (fe) close to 1 in rats
and the minimal loss of the parent drug in the LQYLWUR rat microsomal stability study
strongly suggests that Lee 1599 is predominantly cleared by the renal route. The
excretion ratio (Eratio) was greater than 1 indicating a net active renal secretion process.
The pharmacokinetics of Lee 1599 was similar to that of its parent compound
spectinomycin which was also found to be predominantly eliminated by the renal route
with a total CL of 0.602 L/h/kg in rats. Spectinomycin has a volume of distribution of
0.756 L/kg which was also comparable to Lee 1599 indicating that it mainly distributes
into the extracellular body water [66].
PBPK model development in rats
A PBPK model for Lee 1599 was developed in rats based after IV administration
of 10 mg/kg based on the inputs on physicochemical properties listed in Table 5-1 and
rat specific ADME properties including clearance and protein binding listed in Table 5-2.
The model predicted pharmacokinetic profile in rat was initially unable to
reasonably describe the distribution phase with under-prediction observed at the lower
concentrations suggesting poor estimation of partition coefficients (Figure 5-2).
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Table 5-2.
Route
IV

Pharmacokinetic parameters and protein binding of Lee 1599 in rats

Dose
(mg/kg)

AUCINF
(h·μg/mL)

Vss
(L/kg)

CL
(L/h/kg)

fu

Eratio

fe

10

15.0

0.467

0.666

0.558

2.76

0.883

Microsomal
stability
(% Remaining)
100

Abbreviations: AUCINF: Area under the curve from time zero extrapolated to infinity; Vss:
Volume of distribution at steady state, CL, Total body clearance; fu, Average of the
fraction of drug unbound to plasma proteins at 0.5 and 5mg/L; fe, Fraction excreted
unchanged in the urine; Microsomal Stability, % of Lee 1599 remaining after 90 min
incubation; Eratio, Excretion ratio.
All values are shown as the means.
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Table 5-3.

Pharmacokinetic parameters and protein binding of Lee 1599 in mice
Route
SC

Dose
AUCINF
Vz/F
CL/F
fu
(mg/kg) (h·μg/mL) (L/kg) (L/h/kg)
200
159
0.499
1.25
0.632

Abbreviations: AUCINF: Area under the curve from time zero extrapolated to infinity;
VZ/F, Volume of distribution corrected for bioavailability, CL/F, Total body clearance
corrected for bioavailability; fu, Average of the fraction of drug unbound to plasma
proteins at 0.5 and 5mg/L; fe, Fraction excreted unchanged in the urine; Microsomal
Stability, % of Lee 1599 remaining after 90 min incubation; Eratio, Excretion ratio.
All values are shown as the means.
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Figure 5-2. Observed and PBPK model-simulated Lee 1599 total plasma
concentration-time profile in rats after a single intravenous (IV) dose of 10 mg/kg.
Solid red line represents simulation result and blue circles represent mean observed data
with standard error bars.
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The model was further refined through comparison of PBPK-model predicted and
observed concentration-time profiles in rat via optimization of partition coefficients
through manual adjustment of cLogP from -2.5 to -0.50. The rationale for modifying the
cLogP was based on the premise that software quite often overestimates the
hydrophilicity of polar compounds. Additionally, the online database ChemDplus
Advanced (http://chem.sis.nlm.nih.gov/chemidplus) reported a LogP of -0.82 for the
parent compound spectinomycin, and this supports the modification in the cLogP of Lee
1599. This change resulted in improved model fits with the predicted parameter values
within 2 folds of the observed values (Figure 5-3 and Table 5-4) and the final model was
updated with cLogP of -0.5.
Application of the PBPK model in mice
The optimized PBPK model developed based on concentration-time data in rats
was subsequently prospectively tested to predict the Lee 1599 concentration-time profile
in mice after SC dosing. The clearance and plasma protein binding (fu) were updated with
the mouse-specific, experimentally determined values (Table 5-3). All other drugspecific parameters remained unchanged. The absorption phase after SC administration
was best described by a first-order input to the plasma with an absorption half-life of 13
minutes. Overall, the PBPK model for Lee 1599 optimized in rats was successful in
explaining its disposition in mice, with all the predicted pharmacokinetic parameters in
mice within less than 10% deviation of the observed values (Figure 5-4 and Table 5-5).
Scaling of human clearance
After prospective qualification of the PBPK model in mice, the final step was to
predict the pharmacokinetics of Lee 1599 in humans. Unlike in the case with the rat and
mouse model where LQYLYR clearance was used as an input, for the human PBPK model,
clearance was predicted using the Direct Correlation Method. Based on this approach,
human clearance was estimated to be 0.25 L/h/kg. Renal clearance using this approach
assumes that the renal secretion process remains conserved across species [124].
Predictions based on this methodology have been found to correlate well with actual
clearance parameters in humans, except for certain organic anions for which underprediction has been observed because of lower reuptake in human kidneys relative to rats
[124]. Additionally, gender differences in urinary excretion have also been reported in
rats for substrates of organic anion-transporting polypeptide 1 (oatp1) with higher
clearance in females as compared to male rats [128]. Studies are underway to further
characterize the transporters involved in the active secretion of Lee 1599, and its relative
expression in different preclinical species and humans.
The predicted human CL of Lee 1599 was within two folds of the spectinomycin
CL of 0.104 L/h/kg which was observed after IV administration of spectinomycin in
healthy volunteers [129]. It is also important to acknowledge, however that as the human
clearance prediction was based only upon one species, there is substantial uncertainty
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Figure 5-3. Observed and refined PBPK model-simulated Lee 1599 total plasma
concentration-time profile in rat after a single intravenous (IV) dose of 10 mg/kg
Solid red line represents simulation result and blue circles represent mean observed data
with standard error bars.
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Table 5-4.
Comparison of observed versus PBPK model predicted
pharmacokinetic parameters of Lee 1599 in rats after a single intravenous (IV) dose
of 10 mg/kg
Parameter
AUCINF (h·μg/mL)
Vss (L/kg)
CL (L/h/kg)

Observed Predicted
15.0
0.467
0.666

15.0
0.441
0.666

Ratio of
observed / predicted
1
1.06
1

Abbreviations: AUCINF: Area under the curve from time zero extrapolated to infinity; Vss:
Volume of distribution at steady state, CL, Total body clearance.
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Figure 5-4. Observed and PBPK model-simulated Lee 1599 total plasma
concentration-time profile in mice after a single subcutaneous (SC) dose of 200
mg/kg
Solid red line represents simulation result and blue circles represent mean observed data
with standard error bars.
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Table 5-5.
Comparison of observed versus PBPK model predicted
pharmacokinetic parameters of Lee 1599 in mice after a single subcutaneous (SC)
dose of 200mg/kg
Parameter

Observed Predicted

AUCINF (h·μg/mL) 159
Vz /F(L/kg)
0.499
1.25
CL/F (L/h/kg)

168
0.541
1.19

Ratio of
observed / predicted
0.946
0.922
1.05

Abbreviations: AUCINF: Area under the curve from time zero extrapolated to infinity;
VZ/F, Volume of distribution corrected for bioavailability, CL/F, Total body clearance
corrected for bioavailability.
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associated with it. As the development of Lee 1599 gradually progresses into the late
discovery phase, additional pharmacokinetic data will become available in other preclinical species like dogs, which in combination with the existing data could be used for
making a more confident prediction.
Prediction of human pharmacokinetics
Using the human clearance estimate from the Direct Correlation Method along
with an assumed fu of 0.55 (similar to rat and mice fu) in humans, and all other drug
specific parameters unchanged, the PBPK model was used to predict the human
pharmacokinetics (Figure 5-5). The parameters for the simulated virtual pharmacokinetic
profile in humans for dose of 7.5 and 27.5 mg/kg are listed in Table 5-6. In agreement
with the theory of allometry, the predicted weight normalized clearance as well as
volume of distribution were lower than those found in rats and mice.
Based on this model, a dose of 7.5 and 27.5 mg/kg administered once daily via IV
administration will be required to attain similar exposure as observed in mice after SC
administration of 50 mg/kg and 200 mg/kg respectively. This dose range was selected
based on the results of the dose-exposure-response analysis of Lee 1810, a structural
analog of Lee 1599 and a competing lead candidate, which suggested that reasonable
efficacy could be attained within a dose range of 50 mg/kg – 200 mg/kg, dependent on
the dosing interval. The feasibility of achieving the projected dose range of Lee 1599 in
humans is supported by similar dose recommendation for the parent compound
spectinomycin, which is prescribed as single-dose treatment of 2 g spectinomycin
administered by intramuscular injection for the treatment of gonococcal infections and
other associated conditions [130]. Going forward, the exposure differences in mice for
different routes of administration and health status would also need to be studied in order
to obtain a more precise prediction of the efficacious dose range in humans. Additionally,
the dose projection was based on the premise that Lee 1599 will be used as a single agent.
However, in the clinic Lee 1599 will likely be used in combination with other antituberculosis agents, which is assumed to result in a lower dose requirement for Lee 1599.
In summary, the pharmacokinetics of Lee 1599 was described by a PBPK model
in rats and mice, and the model was applied to predict the pharmacokinetics and dose
requirements of Lee 1599 in humans. This model suggests that an efficacious systemic
exposure can be achieved with daily doses feasible in humans, and may be useful during
drug development for understanding the dose requirements of future preclinical and
clinical studies.
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Figure 5-5. Simulated time course of Lee 1599 total plasma concentration after
intravenous (IV) dose of 7.5 (top) and 27.5 mg/kg (bottom) in a virtual population
human
The solid red line represents the median and the red band represents the range 5% to 95%
for the 100 simulated profiles in a virtual human population.
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Table 5-6.
Model predicted pharmacokinetic parameters of Lee 1599 in humans
after intravenous (IV) dose of 7.5 and 27.5 mg/kg, which results in a similar
exposure after subcutaneous (SC) injection in mice of 50 and 200 mg/kg respectively
Dose
7.5 mg/kg

27.5 mg/kg

Lower
Upper
Parameter
5%
Median 95%
range
range
Cmax (μg/mL)
34.6
41.2
56.2
AUCINF (h·μg/mL)
15
26.6
50.8
Vss (L/kg)
0.322
0.254
0.239
CL (L/h/kg)
0.499
0.282
0.148
Cmax (μg/mL)
AUCINF (h·μg/mL)
Vss (L/kg)
CL (L/h/kg)

160
55.1
0.322
0.499

165
97.6
0.254
0.282

206
186
0.239
0.148

Abbreviations: Cmax, Peak concentration, AUCINF: Area under the curve from time zero
extrapolated to infinity; Vss: Volume of distribution at steady state, CL, Total body
clearance.
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CHAPTER 6. SUMMARY
The antibiotic spectinomycin is a bacterial protein synthesis inhibitor with a
distinct mechanism of action and a high safety margin, but it is ineffective against
0\FREDFWHULXPWXEHUFXORVLV (0WE). Using structure-based design, a novel class of amide
derivatives of spectinomycin was generated with potent antitubercular activity which
blocks native efflux from the tuberculosis cell. I hypothesized that the application of
translational PK/PD approaches would facilitate further development of the lead
compounds Lee 1599 and Lee 1810.
To identify the main driver for efficacy of lead spectinamide Lee 1810, a dosefractionation study was performed in BALB/c mice infected with a low dose aerosol of
0WE which were treated with different dosing regimens of Lee 1810. Dosing was
continued for 4 weeks with blood sampling at 0.25 h and 8 h post dose from each mice in
the last week, followed by a washout period after which the mice were sacrificed and the
lungs removed for measurement of colony forming units (CFU). The concentrations at
0.25 h increased in a dose-proportional fashion until 100 mg/kg and then increased more
than dose-proportional between 200 – 400 mg/kg. However, concentrations at 8 h were
found to be dose-proportional across the entire dose range. A simultaneous population
pharmacokinetic analysis of sparse data from the dose-fractionation study and intensive
data from a pharmacokinetic study in healthy mice was performed using nonlinear mixed
effects modeling. A two-compartment model with first-order absorption and linear
elimination from the central compartment characterized the plasma concentration–time
profile of Lee 1810. The nonlinearity in C0.25 above 100 mg/kg was described using a
higher absorption rate for those dose levels and can potentially be explained by an
increased absorption rate associated with faster diffusion at the subcutaneous site of
administration. Healthy mice had 56.5 % lower clearance, 69% lower volume of
distribution of the central compartment and 69.6 % lower intercompartmental clearance
as compared to infected mice. These differences could be a result of differences in
plasma binding protein concentrations, an altered hydration status in infected animal,
and/or altered hemodynamics in this chronic disease state.
A two-subpopulation natural bacterial growth model adequately described the
dynamic change in bacterial count in the untreated group of mice plus data obtained from
previously performed studies and from the literature. 0WE is a slow growing bacterium
with a growth rate constant Krep estimated by the model as 0.0327 h-1, which is within the
range of growth rate constants found in the literature. To account for the bacterial kill by
the immune system of mice, a first-order death rate constant (Kir ) was introduced for both
of the subpopulations.
A sequential PK/PD analysis was performed by integrating the individual SRVW
KRF parameter estimates from the population pharmacokinetic analysis with the bacterial
growth model via an exposure-dependent bacterial kill function characterized by a
sigmoid Emax model for describing the overall rate of change in lung CFU with different
dosing regimens. The PK/PD model could reasonably describe the microbial kill of Lee
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1810 with EC50 , Emax and Ȗ estimated as 239 μg/mL, 11.9 h-1 and 2.40, respectively. A
high value of the Hill coefficient is a typical characteristic observed for other
concentration-dependent killing antibiotics. EC50 (239 μg/mL) was found to be much
higher than MIC (1.6 μg/mL) of Lee 1810. EC50 describes the time course of drug effect
and is much more realistic parameter to compare potency of compounds rather than the
MIC, which represents the lowest static concentration at which no growth of
microorganism is visible to the naked eye. Lee 1810 demonstrated concentrationdependent antibacterial kill which suggests that the higher the peak concentration is
above MIC, the better would be the microbial kill. Although Lee 1810 has a short halflife, its concentration–dependent killing characteristics and moderate LQYLWUR post
antibiotic effect of 20 h support its intermittent dosing which is also commonly used for
aminoglycoside antibiotics.
Spectinamides are highly water soluble and poorly permeable resulting in limited
oral bioavailability and hence are usually administered through the subcutaneous route in
mice. Additionally, since the lungs are the main organ affected in pulmonary
tuberculosis, the efficacy of Lee 1599 was evaluated after IT administration in a mouse
model of 0WE infection. The results of this study suggest significantly improved efficacy
compared to SC administration. Based on these observations, I hypothesized that IT
delivery of Lee 1599 has better efficacy compared to SC administration in mice due to
higher concentrations of drug at the site of infection in the lungs for a longer duration of
time. This hypothesis was tested by comparing the biodistribution of Lee 1599 in vital
organs, including the lungs, in mice with both routes of administration. The rate and
extent of absorption was almost two times higher with IT as compared to SC
administration. This can be explained by the natural capacity of lungs to allow
permeation of small molecules, and it also suggests that the drug is likely being delivered
to the peripheral regions of the lungs which is desirable as 0WE usually resides in these
regions. As expected, highest exposure of Lee 1599 after IT administration was attained
in the lungs which was 2.5 times higher than in plasma. Dibasic compounds including
Lee 1599 usually have longer lung retention which may be explained by the phenomena
of ‘lysosomal trapping’ where the basic drug gets accumulated in the acidic compartment
of lysosomes of alveolar macrophages and acts as a reservoir. Even though Lee 1599 is
highly hydrophilic, it was found to slightly accumulate in tissues such as liver and kidney
suggesting the potential role of transporters involved in the uptake into cells in these
organs. Overall, this study supports the pulmonary route as a potential pathway for the
treatment of tuberculosis with Lee 1599.
The projection of human pharmacokinetics from preclinical species is one of the
most challenging steps in drug development. Physiologically-based pharmacokinetic
(PBPK) modelling is an approach which has recently gained importance for cross-species
extrapolation of pharmacokinetics. It utilizes the anatomical and physiological parameters
of the species along with the drug-specific inputs obtained by LQVLOLFR/LQYLYR
extrapolation or LQYLWUR/LQYLYR extrapolation for prediction of pharmacokinetics. My
objective was to develop a PBPK model for describing the pharmacokinetics of Lee 1599
in rats and mice, and perform human pharmacokinetics predictions in order to address the
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hypothesis that systemic exposures efficacious in mice are feasible to be achieved in
humans.
The pharmacokinetics of Lee 1599 in rats were well described by the optimized
PBPK model. The predicted systemic exposure, clearance and volume of distribution
were within 10% of their observed values. The model was subsequently qualified by
reasonably predicting murine pharmacokinetic behavior. The subsequently predicted,
dose normalized human clearance and volume of distribution were as expected lower
than those found in rats and mice. An IV dose of 7.5 mg/kg and 27.5 mg/kg administered
once daily was predicted to match the efficacious exposure observed in mice after SC
administration of 50 mg/kg and 200 mg/kg respectively, and appears to be achievable in
patients.
In conclusion, translational PK/PD approaches have been successfully used for
further the further development and characterization of the spectinamide lead compounds
Lee 1599 and Lee 1810. The results from the above studies will be helpful in identifying
and optimizing dosing regimens which can strike a balance between bacterial count
reduction, adverse effects, and emergence of resistance. Pulmonary delivery offers an
innovative solution to overcome the limitation of poor oral bioavailability of
spectinamides, and also opens up new opportunities to further improve efficacy. PBPKmodeling based interspecies scaling suggests that therapeutically effective exposures can
be achieved with doses that are feasible to be administered to humans.
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